| Date | Title | | | 01/27/10 | Amylin Pharmaceuticals Reports 2009 Financial Results| 2009 Non-GAAP Operating Loss Improves by 57% Over 2008SAN DIEGO, Jan. 27, 2010 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2009. The Company reported total revenue of $758.4 million for the year ended December 31, 2009, which includes net product sales of $754.0 million. Non-GAAP operating loss was $58.7 million for the year, compared to $137.2 million for 2008. Net loss excluding restructuri... |
|  | | 01/20/10 | Amylin Pharmaceuticals to Webcast Year-End Financial Results| SAN DIEGO, Jan. 20, 2010 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2009 on Wednesday, January 27, 2010 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the fourth quarter and year ended December 31, 2009.
The call will be webcast live throug... |
| | | 01/11/10 | Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference| SAN FRANCISCO, Jan. 11, 2010 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced the 2010 corporate priorities that will position the Company to address the dual epidemics of diabetes and obesity, achieve positive operating cash flow by the end of the year and place the Company on the path to operating profitability by the end of 2011. The news was presented by Daniel M. Bradbury, president and chief executive officer, at the 28th Annual J.P. Morgan Healthcare... |
| | | 01/04/10 | Amylin Pharmaceuticals to Present at J.P. Morgan Healthcare Conference| SAN DIEGO, Jan 04, 2010 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11, 2010 at 6:30 p.m. ET / 3:30 p.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.
The live presentation and break-out session will be webcast, and a recording will be made available following the event. The webcast and ... |
| | | 12/15/09 | Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study| SAN DIEGO & INDIANAPOLIS & CAMBRIDGE, Mass., Dec 15, 2009 (BUSINESS WIRE) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company
(NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive
results from a head-to-head study comparing exenatide once weekly, an
investigational diabetes therapy, to BYETTA(R) (exenatide)injection
taken twice daily, in patients with type 2 diabetes. After 24 weeks of
treatment, patients taking e... |
| | | 12/08/09 | Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab| SAN DIEGO, Dec 08, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Deutsche Bank Biotech Boston Confab on Tuesday, December 15, 2009 at 1:35 p.m. ET / 10:35 a.m. PT inBoston. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.
The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessi... |
| | | 11/05/09 | Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference|
SAN DIEGO, Nov. 5, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 18th Annual Credit Suisse Healthcare Conference in Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. PT / 1:00 p.m. ET. Mark Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals, will be providing a corporate overview.
The audio portion of the presentation will be webcast and a recording will be made availa... |
| | | 11/02/09 | Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update|
SAN DIEGO and INDIANAPOLIS, Nov. 2, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection.
"The FDA update issued today aligns with the BYETTA label approved last week. The current label reflects our understanding of post-marketing reports of renal events and provides physicians ... |
| | | 11/01/09 | Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity|
SAN DIEGO and OSAKA, Japan, Nov. 1, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metre... |
| | | 10/30/09 | BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes|
SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for use onl... |
| | | 10/22/09 | Amylin Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference| SAN DIEGO, CA, Oct 22, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 4th Annual BIOCOM Investor Conference in San Diego on Monday, October 26, 2009 at 9:30 a.m. PT / 12:30 p.m. ET. David Maggs, M.D., vice president of research and development strategic relations, will be providing a corporate overview.
The audio portion of the presentation will be webcast and a recording will be made available following the event. The webcast an... |
| | | 10/20/09 | Amylin Pharmaceuticals Reports Third Quarter Financial Results| Non-GAAP Operating Loss Improves by 64% to $41.6 Million in First Nine Months of 2009 Compared to Same Period in 2008SAN DIEGO, Calif., Oct 20, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2009. The Company reported total revenue of $211.2 million for the third quarter, including net product sales of $192.9 million. Non-GAAP operating income was $0.6 million for the quarter ended Septemb... |
| | | 10/19/09 | Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009| Phase 2 Pramlintide/Metreleptin Combination Treatment Data Accepted for Oral Presentation at Late Breaking Clinical Trial Symposium
SAN DIEGO, Calif., Oct. 19, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment c... |
| | | 10/13/09 | Amylin Pharmaceuticals to Webcast Third Quarter Results|
SAN DIEGO, Calif., Oct. 13, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the third quarter of 2009 on Tuesday, October 20, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2009.
The call will be webcast live throug... |
| | | 09/24/09 | Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009| SAN DIEGO, Calif., INDIANAPOLIS, Ind., and CAMBRIDGE, Mass., Sept. 24, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, taking place from Sept. 29 to Oct. 2. The companies will present the latest research findings on BYETTA(R) (exenatide) injection and e... |
| | | 09/10/09 | Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid| Program will Focus on the Potential Treatment of Diabetes
SAN DIEGO and BANGALORE, India, Sept. 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share develo... |
| | | 09/03/09 | Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference|
SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14, 2009 at 9:10 a.m. ET / 6:10 a.m. PT in New York. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.
The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording wil... |
| | | 08/24/09 | Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board| SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that its Board of Directors has elected Paulo
F. Costa as Chairman of the Board, effective immediately.
Mr. Costa was formerly President and Chief Executive Officer of Novartis
U.S. Corporation, where he held several other executive positions, including
Head of the Americas and President and Chief Executive Officer of Novartis
Pharmaceutical Corporation. Prior to joining Novarti... |
| | | 07/21/09 | Amylin Pharmaceuticals Reports Second Quarter Financial Results| Non-GAAP Operating Loss Improves by 50% to $42.2 Million in First Half of 2009
Compared to First Half of 2008
New Drug Application for Exenatide Once Weekly Submitted and Accepted for
Review by FDA
SAN DIEGO, July 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter ended June 30,
2009. The Company reported total revenue of $209.4 million for the quarter
... |
| | | 07/20/09 | Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study| Significant Reductions in Weight and Fewer Reports of Hypoglycemia Compared to
Lantus Also Observed
SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 20
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli
Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today
announced positive results from a study comparing subjects randomized to
either exenatide once weekly or Lantus (insulin glargine). Patients
randomized to ... |
| | | 07/14/09 | Amylin Pharmaceuticals to Webcast Second Quarter Results| SAN DIEGO, July 14 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
second quarter of 2009 on Tuesday, July 21, 2009 at 5:00 p.m. ET/2:00 p.m. PT.
Daniel M. Bradbury, Amylin's president and chief executive officer, will lead
the call. On the same date post-market, Amylin will release financial results
for the second quarter of 2009.
The call will be webcast live through Amylin's corporate Web site and a
... |
| | | 07/09/09 | Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity| Findings Further Support Leptin as Part of Company's Integrated Neurohormonal
Therapy for Obesity (INTO) Strategy
SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced positive results from a 28-week dose-ranging
study of pramlintide/metreleptin, a combination treatment comprising
pramlintide, an analog of the natural hormone amylin, and metreleptin, an
analog of the natural hormone leptin, in overweight and obese p... |
| | | 07/07/09 | New Drug Application for Exenatide Once Weekly Accepted for Review by FDA| SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 7, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA).
Exenatide once weekly is an investigational sustained release medication for type 2 diabetes that is injected subcutaneously and admin... |
| | | 06/17/09 | Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference| SAN DIEGO, June 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Piper Jaffray Europe Conference in London on Wednesday, June 24, 2009 at 10:30 a.m. British Summer Time/ 5:30 a.m. ET. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.
The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webc... |
| | | 06/08/09 | Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009| Cardiovascular Safety and Potential Benefits of Exenatide to be
Prospectively Assessed in Large Outcomes Trial
NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results
from a meta-analysis of cardiovascular (CV) events that showed no increased
risk of CV events associated with BYETTA(R) (exenatide) injection use compared
to a pooled comparator group treated with either placebo or insulin.... |
| | | 06/07/09 | Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009| Improvements in Systolic Blood Pressure and Triglycerides Also Observed
NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY), and Alkermes, Inc. (Nasdaq:
ALKS) today announced long-term, interim results from the DURATION-1 study
that showed sustained glucose control with weight loss, as well as
improvements in systolic blood pressure and triglycerides, through two years
of treatment with exenatide once weekly, ... |
| | | 06/07/09 | Interim Study Results Presented at ADA 2009: Exenatide Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs| Retrospective Cohort Study Included More Than 25,000 BYETTA Patients
Accrued Over Three Years
NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced interim
results from a retrospective study including nearly 260,000 patients that
showed the risk of acute pancreatitis among patients initiating therapy with
BYETTA(R) (exenatide) injection was not increased compared to patients
initiating other ... |
| | | 06/06/09 | Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain: Data Presented at ADA 2009| Additional Analyses Showed Pramlintide Improved Treatment Satisfaction and
Quality of Life
NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced data showing that the use of mealtime SYMLIN(R)
(pramlintide acetate) injection improved glucose control, treatment
satisfaction and quality of life for patients with type 2 diabetes. These
findings were detailed in oral and poster presentations at the 69th Annual
Scientific Sessions of ... |
| | | 06/03/09 | Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference| SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Goldman Sachs Annual Global Health
Care Conference on Tuesday, June 9, 2009 at 10:45 a.m. ET / 7:45 a.m. PT in
New York. Daniel M. Bradbury, president and chief executive officer of Amylin
Pharmaceuticals, will provide a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcas... |
| | | 06/02/09 | Amylin Announces Preliminary Tabulation of Annual Meeting Results| SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that IVS Associates, Inc., the independent
Inspector of Elections for the Company's Annual Meeting of Stockholders held
May 27, 2009, has completed its preliminary tabulation of shareholder votes.
The preliminary tabulation indicates that shareholders voted to re-elect eight
of the Company's current Directors to Amylin's Board of Directors - Adrian
Adams, Steven R. Altman, Teresa Bec... |
| | | 05/29/09 | Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009| SAN DIEGO, May 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that the company will present data for its
FDA-approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R)
(pramlintide acetate) injection, and its investigational diabetes drug
candidate exenatide once weekly at the American Diabetes Association's (ADA's)
69th Annual Scientific Sessions being held in New Orleans from June 5 to 9.
The company will also host an investor pre... |
| | | 05/27/09 | Amylin Announces Preliminary Results of Annual Meeting of Stockholders| SAN DIEGO, May 27 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that, based on a preliminary vote count
provided by its proxy solicitor, shareholders voted to elect at least 10 of
the Company's nominees, including its two new independent nominees, Paul N.
Clark and Paulo F. Costa, to Amylin's Board of Directors at the Company's
Annual Meeting of Stockholders held today. The Company believes that no more
than two of the five dissident nominees (on... |
| | | 05/26/09 | Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today| --Amylin Urges Shareholders to Support the Company's Twelve Nominees
SAN DIEGO, May 26, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reminded its shareholders to use their BLUE proxy card to vote FOR all of Amylin's nominees, including its two new independent Director nominees: Paul N. Clark and Paulo F. Costa. Amylin urges shareholders to disregard any proxy cards received from Carl Icahn and Eastbourne Capital Management, L.L.C.
Amylin's 2009 A... |
| | | 05/20/09 | Amylin Responds to Eastbourne Letter| SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) issued the following statement in response to a May 18, 2009,
letter which Eastbourne Capital Management, L.L.C., made public earlier today:
"After significant efforts and consultation with numerous shareholders,
Amylin has been unable to achieve a settlement with Eastbourne and Carl Icahn
which is in the best interests of ALL shareholders. Of course, we continue to
remain open to new ideas and ... |
| | | 05/15/09 | Amylin Comments on RiskMetrics Report| Urges Stockholders to Vote FOR Amylin Director Nominees on the Blue Proxy
Card Today
RiskMetrics Splits Recommendation in Proxy Contest
SAN DIEGO, May 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today issued the following statement in response to a report
issued by RiskMetrics Group (formerly Institutional Shareholder Services)
regarding Amylin's Annual Meeting of Stockholders to be held on May 27, 2009:
It is important for shareholders t... |
| | | 05/14/09 | Amylin Issues Statement Regarding Open Letter From Icahn| SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today released the following statement in response to Carl
Icahn:
"Icahn Associates has been criticizing our Board for our performance, we
felt it was only fair to point out, according to Icahn's own standards, issues
with his nominees' history.
"Icahn's own performance elsewhere is well documented."
About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to
i... |
| | | 05/12/09 | Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference| SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Deutsche Bank Health Care Conference
on Tuesday, May 19, 2009 at 11:30 a.m. ET / 8:30 a.m. PT in Boston. Daniel M.
Bradbury, president and chief executive officer of Amylin Pharmaceuticals,
will provide a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcast and
recording... |
| | | 05/11/09 | Amylin Sends Letter To Shareholders| Urges Shareholders to Support the Board's Strategy and Vote the BLUE Proxy
Card Today to Elect Amylin's Highly-Qualified Nominees
SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that it is sending the following letter to
shareholders in connection with the Company's Annual Meeting of Stockholders
on May 27, 2009. Amylin urges all shareholders to vote FOR Amylin's Directors
on the BLUE proxy card today and reject the nominees... |
| | | 05/05/09 | Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes| SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., May 5
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli
Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today
announced that a New Drug Application (NDA) for exenatide once weekly has been
submitted to the U.S. Food and Drug Administration (FDA). Exenatide once
weekly is an investigational sustained release medication for type 2 diabetes
that is injected subcutaneously and administered only once a ... |
| | | 05/04/09 | Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market| --Changes Will Result in a 35% Sales Force Reduction and Approximately $45 Million Annual GAAP Operating Results Benefit
SAN DIEGO, May 4, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced a new approach to sales within the diabetes market. Amylin's existing primary care and specialty sales forces will merge into a single organization that brings a specialty approach to endocrinologists and diabetes-focused primary care physicians. The changes... |
| | | 05/01/09 | Amylin Sends Letter to Shareholders| --Urges Shareholders to Support the Board's Strategy and Vote the BLUE Proxy Card Today to Elect Amylin's Highly-Qualified Nominees
SAN DIEGO, May 1, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it is mailing a letter to shareholders in connection with the Company's Annual Meeting of Stockholders on May 27, 2009. Amylin urges all shareholders to vote FOR Amylin's Directors on the BLUE proxy card today and reject the nominees of both... |
| | | 04/29/09 | Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly| Companies Committed to Investing in New Product Presentations for Patients
SAN DIEGO and INDIANAPOLIS, April 29 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced that the companies have agreed in principle to the terms of a
joint supply agreement for an exenatide once weekly pen device. Separately,
the companies announced that they have initiated a phase 1/2 clinical study to
examine a new exenatide once week... |
| | | 04/23/09 | Amylin Issues Statement in Response to Carl Icahn| SAN DIEGO, April 23, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today issued the following statement from James N. Wilson, Lead Independent Director, on behalf of the Amylin Board of Directors:
The Amylin Board of Directors welcomes continued three-way dialogue with Carl Icahn and Eastbourne Capital Management, L.L.C. to find a path to end a proxy contest. We hope that we can reach a resolution that will be in the best interests of all Amylin sharehold... |
| | | 04/16/09 | Amylin Pharmaceuticals Reports First Quarter Financial Results| --Non-GAAP Operating Loss Improves by 55% to $19.9 Million Compared to the First Quarter of 2008
SAN DIEGO, April 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin/Lilly Alliance Restructures Exenatide Operations: Team to Co-locate in San Diego
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended March 31, 2009. The Company reported total revenue of $193.7 million for the quarter ended March 31, 2009, which includes net product sales of $179.3 m... |
| | | 04/09/09 | Amylin Pharmaceuticals to Webcast First Quarter Results| SAN DIEGO, April 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first
quarter of 2009 on Thursday, April 16, 2009 at 5:00 p.m. ET/2:00 p.m. PT.
Daniel M. Bradbury, Amylin's president and chief executive officer, will lead
the call. On the same date post-market, Amylin will release financial results
for the first quarter of 2009.
The call will be webcast live through Amylin's corporate Web site and a
... |
| | | 04/02/09 | Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments| SAN DIEGO, April 2, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today released the following letter from its Lead Independent Director, James N. Wilson, providing shareholders with an update on recent developments:
Dear Fellow Amylin Shareholder:
As Lead Independent Director of Amylin, I am writing you today to provide a summary of exciting business developments at your company, as well as details on the slate of highly qualified and experienced indi... |
| | | 03/31/09 | Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study| SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., March 31, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from DURATION-2, the second in a series of studies designed to test the superiority of exenatide once weekly, an investigational diabetes therapy, as compared to other diabetes medications.
This 26-week clinical study compared exenatide once weekly to max... |
| | | 03/30/09 | Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders| SAN DIEGO, March 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced its director nominees for election at the 2009
Annual Meeting of Stockholders. Over the past several months, the Company's
Corporate Governance Committee, in consultation with other independent
directors, engaged in a rigorous process to identify a slate of highly
qualified and experienced nominees that the Board strongly believes will best
serve the interests of all Amylin stockho... |
| | | 03/26/09 | Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events| Large Cardiovascular Outcomes Study To Be Initiated
Manufacturing Comparability Analysis Complete: Exenatide Once Weekly NDA
Submission Remains On Track
SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., March 26
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli
Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today
announced that a meta-analysis of primary cardiovascular events across
controlled clinical studies of three months or greater,... |
| | | 03/10/09 | Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference| SAN DIEGO, March 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Cowen and Company 29th Annual Health
Care Conference on Tuesday, March 17, 2009 at 5:00 a.m. PT / 8:00 a.m. ET in
Boston. Daniel M. Bradbury, president and chief executive officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. T... |
| | | 01/30/09 | Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices| SAN DIEGO, Jan 30, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) confirmed today that it has received a notice from Amylin shareholder Icahn Capital LP and affiliated funds announcing their intent to nominate a slate of five directors to stand for election at the Company's 2009 annual meeting. The notice from the Icahn group also states their intent to submit a proposal for shareholder approval requesting that the Company reincorporate in the state of Nor... |
| | | 01/29/09 | Amylin Pharmaceuticals Comments on Shareholder 13-D Filing| SAN DIEGO, Jan 29, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) confirmed today that it has reviewed an amended 13-D filing with the Securities and Exchange Commission from Amylin shareholder Icahn Capital LP and affiliated funds announcing their intent to nominate a slate of five directors to stand for election at the Company's 2009 annual meeting. Amylin has not yet received the required notice with respect to this action.
Amylin's Corporate Governance... |
| | | 01/27/09 | Amylin Pharmaceuticals Reports 2008 Financial Results| Net Product Sales Increased 9% Over 2007 to $765.3 Million; Positive
Operating Cash Flow Targeted By End of 2010
SAN DIEGO, Calif., Jan. 27 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the
quarter and year ended December 31, 2008. The Company reported total revenue
of $202.5 million for the quarter ended December 31, 2008, which includes net
product sales of $184.9 million. Net loss, excluding a charge of $54.9 million
... |
| | | 01/26/09 | Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer| Mihalik Brings Track Record for Generating Sales and Profits in the Diabetes ArenaSAN DIEGO, Jan 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) announced today that Vincent P. Mihalik has been appointed
Senior Vice President, Sales and Marketing and Chief Commercial Officer. Mr.
Mihalik brings more than 30 years of experience across multiple commercial
roles, including global product development, sales and sales management,
product lau... |
| | | 01/21/09 | Amylin Pharmaceuticals to Webcast Year-End Results| SAN DIEGO, Jan 21, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2008 on Tuesday, January 27, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the fourth quarter and year ended December 31, 2008.
The call will be webcast live ... |
| | | 01/12/09 | Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities| SAN FRANCISCO, Jan 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Product and Operational Targets Presented At JPMorgan Healthcare Conference
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced product and operational targets for 2009 that provide the opportunity to transform diabetes and obesity treatment and position the Company to be cash flow positive by the end of 2010. The news was presented by Daniel M. Bradbury, president and chief executive officer, at the JPMorgan ... |
| | | 01/06/09 | Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference| SAN DIEGO, Jan 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the JPMorgan Healthcare Conference in San Francisco on Monday, January 12, 2009 at 10:00 a.m. PT / 1:00 p.m. ET. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a recording will be made available following the event. ... |
| | | 12/11/08 | Plans For Exenatide Once Weekly Nda Submission By End Of First Half Of 2009 Reaffirmed Following Fda Feedback|
Companies Intend To Use Ongoing Study To Meet Manufacturing Comparability Requirements
SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 11 /PRNewswire/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN - News), Eli Lilly and Company (NYSE: LLY - News) and Alkermes, Inc. (Nasdaq: ALKS - News) today announced that the U.S. Food and Drug Administration (FDA) recently indicated that the ongoing extension of the DURATION-1 study is appropriate to use as the basis for demonstrating comparab... |
| | | 12/08/08 | Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission| SAN DIEGO and INDIANAPOLIS, Dec. 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) and Eli Lilly and Company (NYSE: LLY - News) today announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of BYETTA® (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control. It is likely that this review will not be complete by t... |
| | | 11/13/08 | Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference| SAN DIEGO, Nov. 13, 2008 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be presenting at the Lazard Capital Markets
Healthcare Conference in New York on Wednesday, November 19, 2008 at 8:30 a.m.
ET. Daniel M. Bradbury, president and chief executive officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation will be Web cast, and a recording will be made
available following the event. The Web cast and recording will be... |
| | | 11/10/08 | Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction| Changes will result in over $80 million reduction in 2009 cash expenditures
SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced a corporate restructuring that will reduce its
San Diego workforce by approximately 25 percent, or 340 employees, and reduce
anticipated 2009 cash expenditures by more than $80 million. The restructuring
and workforce reduction are part of the Company's business plan to be cash
flow positive by the end of... |
| | | 10/23/08 | Amylin Pharmaceuticals to Present at BIOCOM Investor Conference| SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the BIOCOM Investor Conference in San
Diego on Tuesday, October 28, 2008 at 10:30 a.m. PT. Mark G. Foletta, Amylin's
Senior Vice President of Finance and Chief Financial Officer, will be
providing a corporate overview.
The live presentation will be Web cast, and a recording will be made
available following the event. The Web cast and recording will be accessible
through A... |
| | | 10/21/08 | Amylin Pharmaceuticals Reports Third Quarter Financial Results| Product sales increased 14% over third quarter 2007 to $201 million
SAN DIEGO, Oct. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2008. The Company reported total revenue of $218.4 million for the third quarter, including net product sales of $201.4 million, a 14% increase over the same period in 2007. Net loss for the quarter ended September 30, 2008 was $77.7 million, or $0.57 per share. Net l... |
| | | 10/21/08 | Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly| SAN DIEGO and INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced they have entered into a product supply agreement for
exenatide once weekly, a development compound that, if approved, would become
the first once weekly therapy to treat type 2 diabetes. Under terms of the
agreement, Lilly will make an initial cash payment of $125 million to Amylin,
and Amylin will supply product for sales in t... |
| | | 10/15/08 | Amylin Pharmaceuticals to Webcast Third Quarter Results| SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will Webcast its Quarterly Update Conference Call for the third
quarter of 2008 on Tuesday, October 21, 2008 at 5:00 p.m. ET/2:00 p.m. PT.
Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead
the call. On the same date post-market, Amylin will release financial results
for the third quarter of 2008.
The call will be Webcast live through Amylin's corporate Web site and... |
| | | 10/01/08 | Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society| SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that new data for its pipeline obesity
candidates will be presented at the 2008 Annual Scientific Meeting of The
Obesity Society in Phoenix October 3-7. The Obesity Society's annual meeting
is one of the largest and most comprehensive scientific conferences in the
field of obesity.
Amylin will present scientific data through 11 oral and poster
presentations, showcasing progres... |
| | | 09/10/08 | First Reported Head-to-Head Study Showed BYETTA® (exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels Than Januvia™ (sitagliptin) in Patients With Type 2 Diabetes | Click here for the release.... |
| | | 08/28/08 | Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences| SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Thomas Weisel Healthcare Conference
in Boston on Wednesday, September 3, 2008 at 9:10 a.m. ET, at the BioCentury
NewsMakers Conference in New York on Thursday, September 4, 2008 at 11:30 a.m.
ET, and at the Morgan Stanley Global Healthcare Unplugged Conference in New
York on Tuesday, September 9, 2008 at 10:55 a.m. ET. Mark G. Foletta, Amylin's
Senior Vice President of Fin... |
| | | 08/26/08 | Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA| SAN DIEGO and INDIANAPOLIS, Aug. 26 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) in
a conference call today provided context and additional information regarding
the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior
alert for BYETTA(R) (exenatide) injection referencing pancreatitis. The
companies were aware of the pancreatitis cases referenced in the alert, as
well as others, and previously reported ... |
| | | 08/25/08 | Amylin and Lilly Set Date and Time for Conference Call| Companies Will Discuss Recent FDA Advisory Regarding BYETTA
SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) will Web cast a
conference call on Tuesday, August 26 at 5:00 p.m. ET/2:00 p.m. PT to discuss
the recent FDA advisory on BYETTA(R) (exenatide) injection. Leading the call
for Amylin will be Daniel M. Bradbury, Amylin's President and Chief Executive
Officer and Orville G. Kolterman, M.D., Amylin'... |
| | | 07/21/08 | Amylin Pharmaceuticals Reports Second Quarter Financial Results| Product sales increased 20% over second quarter 2007 to $200 million
SAN DIEGO, July 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter ended June 30,
2008. The Company reported total revenue of $222.0 million for the second
quarter, including net product sales of $200.3 million. Net loss for the
quarter ended June 30, 2008 was $64.8 million, or $0.47 per share. At June
30, 2008, the Company held cash, cash ... |
| | | 07/15/08 | Amylin Pharmaceuticals to Webcast Second Quarter Results| SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will Webcast its Quarterly Update Conference Call for the
second quarter of 2008 on Monday, July 21, 2008 at 5:00 p.m. ET/2:00 p.m. PT.
Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead
the call. On the same date post-market, Amylin will release financial results
for the second quarter of 2008.
The call will be Webcast live through Amylin's corporate Web site and a
... |
| | | 06/09/08 | Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin| Results from a 24-week multi-center, randomized, open-label study presented at
ADA 2008
SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) today announced data showing that the use of mealtime
SYMLIN(R) (pramlintide acetate) injection with basal insulin therapy for
24 weeks resulted in more patients achieving diabetes treatment goals of
improved glucose control without weight gain or hypoglycemia compared to th... |
| | | 06/09/08 | After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008| Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved Glucose Control in Patients Switching from Exenatide Taken Twice a Day
SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN - News), Eli Lilly and Company (NYSE: LLY - News), and Alkermes, Inc.
(Nasdaq: ALKS - News) today announced results from a 52-week open-label clinical
study that showed the durable efficacy of exenatide once weekly, a long-acting
release formulation of exenatide. Pa... |
| | | 06/07/08 | Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight| DURATION-1 Data Presented at the 68th Annual Scientific Sessions of the American Diabetes Association
SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN - News), Eli Lilly and Company (NYSE: LLY - News), and Alkermes, Inc.
(Nasdaq: ALKS - News) announced results from a 30-week study that compared the
efficacy of exenatide once weekly, a long-acting release formulation of
exenatide, to BYETTA® (exenatide) injection. Type 2 diabetes patients
treated wi... |
| | | 06/07/08 | Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss| Submitted to FDA for Stand-Alone Therapy in Q1 2008
SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN - News) and Eli Lilly and Company (NYSE: LLY - News) today announced
additional results from a study of patients with type 2 diabetes who were
unable to achieve glycemic control through diet and exercise alone and were
treated with either monotherapy (stand-alone) BYETTA® (exenatide) injection
taken twice daily or placebo. Study findings showed that... |
| | | 06/05/08 | Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference| SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Goldman Sachs Global Healthcare
Conference in Dana Point on Wednesday, June 11, 2008 at 1:20 p.m. PT. Daniel
M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals,
will be providing a corporate overview.
The live presentation will be Web cast, and a recording will be made
available following the event. The Web cast and recording will be accessible... |
| | | 06/02/08 | Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008| SAN DIEGO, June 2, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that the company will present new data for its
FDA-approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R)
(pramlintide acetate) injection, and its pipeline diabetes and obesity drug
candidates at the American Diabetes Association's 68th Annual Scientific
Sessions (ADA) being held in San Francisco, CA from June 6 to 10. The company
will also h... |
| | | 05/23/08 | Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders| SAN DIEGO, May 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will Web cast its Annual Meeting of Stockholders on Friday, May
30, 2008 at 11:00 a.m. PT from the company's corporate headquarters in San
Diego, CA. Following the Annual Meeting, Daniel M. Bradbury, President and
Chief Executive Officer of Amylin Pharmaceuticals, will be providing a
corporate overview.
The live presentation will be Web cast, and a recording will be made
available following t... |
| | | 05/22/08 | Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference| SAN DIEGO, May 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the FBR Capital Markets Investor
Conference in New York on Wednesday, May 28, 2008 at 9:45 a.m. ET / 6:45 a.m.
PT. David M. Kendall, M.D., Executive Director, Medical Affairs of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcast a... |
| | | 05/12/08 | Amylin Pharmaceuticals to Present at Baird Growth Stock Conference| SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Baird Growth Stock Conference on
Wednesday, May 14, 2008 at 3:05 p.m. CT / 1:05 p.m. PT in Chicago. Mark G.
Foletta, Senior Vice President, Finance and Chief Financial Officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webca... |
| | | 05/07/08 | Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference| SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Bank of America Healthcare Conference
on Tuesday, May 13, 2008 at 10:00 a.m. PT in Las Vegas. Michael York, Senior
Director of Investor Relations of Amylin Pharmaceuticals, will be providing a
corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcast and
recording will be acces... |
| | | 05/05/08 | Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity| Preclinical findings of amylin/leptin synergy and translational Phase 2A
clinical results published online today in Proceedings of the National Academy
of Sciences of the United States of America
SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced the initiation of a Phase 2B clinical study
evaluating various dosing combinations of pramlintide, an analog of the
natural hormone amylin, and recombinant human leptin ... |
| | | 04/30/08 | Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference| SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced it has re-scheduled its presentation time at
the Morgan Stanley Global Healthcare Unplugged Conference in Key Biscayne, FL
to Thursday, May 1, 2008 at 3:00 p.m. ET / 12:00 p.m. PT. Previously, the
presentation had been scheduled for 9:20 a.m. ET / 6:20 a.m. PT. Daniel M.
Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals,
will be providing a corporate overvie... |
| | | 04/25/08 | Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference| SAN DIEGO, April 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Morgan Stanley Global Healthcare
Unplugged Conference in Key Biscayne, FL on Thursday, May 1, 2008 at
9:20 a.m. ET / 6:20 a.m. PT. Daniel M. Bradbury, President and Chief Executive
Officer of Amylin Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made ava... |
| | | 04/21/08 | Amylin Pharmaceuticals Reports First Quarter Financial Results| SAN DIEGO, April 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter ended March
31, 2008. The Company reported total revenue of $197.2 million for the first
quarter, which includes net product sales of $178.7 million. Net loss for the
quarter ended March 31, 2008 was $68.8 million, or $0.51 per share. At March
31, 2008, the Company held cash, cash equivalents and short-term investments
of approximately $1,033.9 m... |
| | | 04/15/08 | Amylin Pharmaceuticals to Webcast First Quarter Results| SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first
quarter of 2008 on Monday, April 21, 2008 at 8:30 a.m. ET/5:30 a.m. PT. Daniel
M. Bradbury, Amylin's President and Chief Executive Officer, will lead the
call. On the same date pre-market, Amylin will release financial results for
the first quarter of 2008.
The call will be webcast live through Amylin's corporate website and a
re... |
| | | 01/31/08 | Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference| SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Merrill Lynch Global Pharmaceutical,
Biotechnology & Medical Device Conference in New York on Wednesday, February
6, 2008 at 1:00 p.m. ET / 10:00 a.m. PT. Mark G. Foletta, Senior Vice
President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, will
be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
record... |
| | | 01/28/08 | Amylin Pharmaceuticals Reports 2007 Financial Results| Net product sales increased 48% over 2006 to $701 million
SAN DIEGO, Jan. 28 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter and year ended
December 31, 2007. The Company reported total revenue of $222.0 million for
the quarter ended December 31, 2007, which includes net product sales of
$194.7 million. Net loss was $76.9 million, or $0.57 per share for the quarter
ended December 31, 2007. Net loss for the qua... |
| | | 01/22/08 | Amylin Pharmaceuticals to Webcast Year-End Results| SAN DIEGO, Jan 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
fourth quarter and full year 2007 on Monday, January 28, 2008 at 5:00 p.m.
ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's President and Chief Executive
Officer, will lead the call. On the same date post market, Amylin will release
financial results for the fourth quarter and year ended December 31, 2007.
The call will... |
| | | 01/07/08 | PHOTO ADVISORY -- SYMLIN Pen-Injector Devices Now Available| Editors are advised that a high-resolution photo is available to accompany
the news release, LAM117, SYMLIN Pen-Injector Devices Now Available, issued
earlier today by Amylin Pharmaceuticals, Inc.
Caption: Amylin Pharmaceuticals, Inc. announced today the availability of
the SymlinPen(TM) 120 and the SymlinPen(TM) 60 pen-injector devices for
administering SYMLIN(R) (pramlintide acetate) injection. These new pre-filled
pen-injector devices feature simple, fixed dosing to improve mea... |
| | | 01/07/08 | SYMLIN Pen-Injector Devices Now Available| SymlinPen Offers Convenient SYMLIN Administration for Enhanced Glucose Control
With Potential Weight Loss
SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) announced today the availability of the SymlinPen(TM) 120 and
the SymlinPen(TM) 60 pen-injector devices for administering SYMLIN(R)
(pramlintide acetate) injection. These new pre-filled pen-injector devices
feature simple, fixed dosing to improve mealtime glucose contro... |
| | | 01/02/08 | Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference| SAN DIEGO, Jan. 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the JPMorgan Healthcare Conference in San
Francisco on Monday, January 7, 2008 at 10:00 a.m. PT / 1:00 p.m. ET. Daniel
M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals,
will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcast and
r... |
| | | 12/06/07 | Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes| - FDA Submission Planned in First Half of 2008 -
SAN DIEGO and INDIANAPOLIS, Dec. 6 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced study results from a 24-week study of monotherapy, or
stand-alone, BYETTA (exenatide) injection taken twice daily in drug-naive
patients with type 2 diabetes. Study participants taking 5 mcg or 10 mcg of
monotherapy BYETTA twice daily showed significant reductions in ... |
| | | 11/30/07 | Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program| SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Nasdaq 20th Investor Program in
London on Thursday, December 6, 2007 at 7:15 a.m. PT / 3:15 p.m. GMT local
time in the UK. Berthold Lensker, Ph.D., Executive Director of European
Operations, will be providing a corporate overview of Amylin Pharmaceuticals.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast an... |
| | | 11/21/07 | Amylin Pharmaceuticals to Present at Research & Development Day| SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at its Research & Development (R&D) Day on
Wednesday, November 28, 2007 at 10:00 a.m. ET at the Grand Hyatt Hotel in New
York.
"Amylin is focused on bringing innovative medicines with life-changing
therapeutic potential to patients through our sustainable approach to the
discovery and development of drugs," said Daniel M. Bradbury, President and
Chief Executive Officer of Am... |
| | | 11/15/07 | Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study| Findings validate novel integrated neurohormonal treatment of obesity (INTO)
strategy
SAN DIEGO, Nov. 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced positive results from a 24-week
proof-of-concept study with pramlintide, an analog of human amylin, and
recombinant human leptin (r-metHuLeptin; metreleptin) combination treatment in
overweight or obese subjects. At study end, pramlintide/metreleptin treatment
re... |
| | | 10/31/07 | Amylin Pharmaceuticals to Webcast Conference Call| SAN DIEGO, Oct 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast a conference call on Wednesday, October 31, 2007
at 8:30 a.m. ET/5:30 a.m. PT to discuss today's release of the once-weekly
exenatide long-acting release study results. Daniel M. Bradbury, Amylin's
President and Chief Executive Officer, will lead the call.
The call will be webcast live through Amylin's corporate website and a
recording will be made available fo... |
| | | 10/31/07 | Exenatide Once Weekly Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study| - Both Groups Experienced Significant Weight Loss - - New Drug Application Filing Planned by the End of the First Half of 2009 -SAN DIEGO & INDIANAPOLIS & CAMBRIDGE, Mass., Oct 31, 2007 (BUSINESS WIRE) -- Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Eli Lilly and Company
(NYSE: LLY) and Alkermes, Inc. (NASDAQ: ALKS) today announced positive
results from a 30-week comparator study of once-weekly exenatide
long-acting release (LAR) injection and BYETTA(R) (exenatide)
injection taken twice dail... |
| | | 10/30/07 | Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors| SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Adrian Adams has been elected to the
company's Board of Directors effective immediately.
"We are very pleased to welcome Adrian to the Amylin Board," said Daniel
M. Bradbury, President and CEO of Amylin Pharmaceuticals. "His international
experience as a highly innovative, strategic business leader, combined with a
track record of building organizations and delivering optim... |
| | | 10/29/07 | Amylin Pharmaceuticals to Present at BIOCOM Investor Conference| SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the BIOCOM Investor Conference on
Thursday, November 1, 2007 at 9:30 a.m. PT in San Diego. Daniel M. Bradbury,
President and Chief Executive Officer of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
through Amylin... |
| | | 10/17/07 | Amylin Pharmaceuticals Reports Third Quarter Financial Results| Net product sales increased 28% over third quarter 2006 to $177 million
SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter ended
September 30, 2007. The Company reported total revenue of $190.0 million for
the third quarter, including net product sales of $177.4 million. Net loss
for the quarter ended September 30, 2007 was $39.8 million, or $0.30 per
share. At September 30, 2007, the Company he... |
| | | 10/11/07 | Amylin Pharmaceuticals to Webcast Third Quarter Results| SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the third
quarter of 2007 on Wednesday, October 17, 2007 at 5:00 p.m. ET/2:00 p.m. PT.
Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead
the call. On the same date post market, Amylin will release financial results
for the third quarter of 2007.
The call will be webcast live through Amylin's corporate website and ... |
| | | 10/01/07 | FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use| SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) announced today that the U.S. Food and Drug Administration
(FDA) has approved the SymlinPen(TM) 120 and the SymlinPen(TM) 60 pen-injector
devices for administering SYMLIN(R) (pramlintide acetate) injection. These
new pre-filled pen-injector devices feature simple, fixed dosing to improve
mealtime glucose control.
"SymlinPen 120 and SymlinPen 60 offer patients improved convenience and
accuracy,... |
| | | 09/14/07 | Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes| SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) management will be presenting a corporate overview at an
investor reception during the 43rd Annual Meeting of the European Association
for the Study of Diabetes (EASD) on Wednesday, September 19, 2007 at 4:30 a.m.
PT / 1:30 p.m. CET local time in Amsterdam, Netherlands.
The live presentation will be webcast, and recordings will be made
available following the event. The webcast and recording ... |
| | | 08/31/07 | Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference| SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the BioCentury NewsMakers Conference on
Thursday, September 6, 2007 at 2:30 p.m. ET in New York, at the Thomas Weisel
Healthcare Conference on Friday, September 7, 2007 at 9:10 a.m. ET in Boston
and at the Bear Stearns Healthcare Conference on Monday, September 10, 2007 at
9:00 a.m. ET in New York. Daniel M. Bradbury, President and Chief Executive
Officer of Amylin Pharmaceuti... |
| | | 08/07/07 | Amylin Resale Registration Statement Declared Effective by SEC| SAN DIEGO, Aug 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that on August 7, 2007, it filed with the
Securities and Exchange Commission (the "SEC") a resale registration statement
on Form S-3 (the "Registration Statement") that was effective immediately upon
filing with the SEC. Amylin filed the Registration Statement to satisfy
certain of its obligations under a registration rights agreement that Amylin
entered int... |
| | | 07/23/07 | Amylin Pharmaceuticals Reports Second Quarter Financial Results| Net Product Sales Increased 54% Over Second Quarter 2006 to $167 Million
SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter ended June 30,
2007. The Company reported total revenue of $197.0 million for the second
quarter, including net product sales of $167.3 million. Net loss for the
quarter ended June 30, 2007 was $45.0 million, or $0.34 per share. At June
30, 2007, the Company held cash, cas... |
| | | 07/16/07 | Amylin Pharmaceuticals to Webcast Second Quarter Results| SAN DIEGO, July 16 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
second quarter of 2007 on Monday, July 23, 2007 at 5:00 p.m. ET/2:00 p.m. PT.
Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead
the call. On the same date post market, Amylin will release financial results
for the second quarter of 2007.
The call will be webcast live through Amylin's corporate website and a
r... |
| | | 06/25/07 | BYETTA offers added benefits of progressive weight loss and improved beta cell function in an analysis of the longest extension study to date| CHICAGO, June 25, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced three- year, open-label study results that showed treatment with BYETTA(R) (exenatide) injection was associated with sustained blood sugar control and progressive weight loss in people with type 2 diabetes. These findings were presented at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago... |
| | | 06/24/07 | BYETTA® Study Showed Comparable Blood Glucose Control to Insulin |
-- BYETTA offers the added benefits of progressive weight loss and lower risk of hypoglycemia --
CHICAGO, IL, June 24, 2007 - Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced study results comparing treatment with BYETTA® (exenatide) injection with insulin glargine in people with type 2 diabetes. Study findings showed comparable improvements in blood sugar control with BYETTA and insulin glargine therapies, with weight loss and lower inci... |
| | | 06/23/07 | SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes| Improved Glucose Control and Reduced Weight without Increased Incidence of
Hypoglycemia
CHICAGO, June 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) announced today study results showing SYMLIN(R) (pramlintide
acetate) injection used in conjunction with basal insulin improved glucose
control and reduced weight without increased hypoglycemia in patients with
type 2 diabetes inadequately controlled with insulin glargine and ora... |
| | | 06/23/07 | BYETTA(R) Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes| - BYETTA also Showed Sustained Improvements in Blood Glucose Control and Progressive Weight Loss -CHICAGO, June 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results
from a study that showed BYETTA(R) (exenatide) injection sustained
improvements in blood sugar levels and progressive weight loss through three
and a half years of therapy. BYETTA treatment was also associated with
imp... |
| | | 06/19/07 | Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007| SAN DIEGO, June 19 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that data featuring its approved diabetes
drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate)
injection, and its pipeline candidates will be presented at the American
Diabetes Association's (ADA) 67th Annual Scientific Sessions being held in
Chicago, IL from June 22 to 26. The company will also host an investor
presentation during the meeting that will be ava... |
| | | 06/08/07 | Amylin Pharmaceuticals to Present at Goldman Sachs Healthcare Conference| SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Goldman Sachs Healthcare Conference
on Thursday, June 14, 2007 at 9:20 a.m. PT in Laguna Nigel, CA. Daniel M.
Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals,
will be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
t... |
| | | 06/06/07 | Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $75 Million of Convertible Senior Notes| SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that the initial purchasers in its recent
private placement of $500 million of 3.00% convertible senior notes due 2014
have elected to exercise their option to purchase an additional $75 million in
principal amount of the notes. The offering is being made pursuant to an
exemption from registration under the Securities Act of 1933, as amended. The
exercise of the option will bring t... |
| | | 06/05/07 | Amylin Pharmaceuticals, Inc. Announces Pricing of Convertible Senior Notes| SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) announced today the pricing of a private placement of
$500 million aggregate principal amount of 3.00% convertible senior notes due
2014. The offering is made pursuant to an exemption from registration under
the Securities Act of 1933, as amended (the "Securities Act"). The private
placement is expected to close on June 8, 2007, subject to customary closing
conditions.
The notes will pay inte... |
| | | 06/04/07 | Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes| SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) announced today that it intends to offer $400 million of
convertible senior notes for sale in a private placement. The offering will
be made pursuant to an exemption from registration under the Securities Act of
1933, as amended (the "Securities Act"). The convertible senior notes will be
convertible into shares of Amylin common stock, subject to Amylin's right to
irrevocably elect to settle conve... |
| | | 05/24/07 | Amylin Pharmaceuticals to Present at Banc of America Healthcare Conference| SAN DIEGO, May 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Banc of America Healthcare Conference
on Wednesday, May 30, 2007 at 12:40 p.m. PT in Las Vegas. Alice Bahner,
Executive Director of Investor Relations of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
through... |
| | | 05/17/07 | Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders| SAN DIEGO, May 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Annual Meeting of Stockholders on Wednesday,
May 23, 2007 at 10:00 a.m. Pacific Time from the company's corporate
headquarters in San Diego, CA. Following the Annual Meeting, Daniel M.
Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals,
will be providing a corporate overview.
The presentation will be webcast live, and a recording will be made
available f... |
| | | 04/26/07 | Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference| SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Morgan Stanley Global Healthcare
Conference on Wednesday, May 2, 2007 at 9:30 a.m. ET in Miami. Daniel M.
Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals,
will be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
th... |
| | | 04/16/07 | Amylin Pharmaceuticals Reports First Quarter Financial Results| Net product sales increase to $162 million
SAN DIEGO, April 16 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter ended March
31, 2007. The Company reported total revenue of $172.0 million for the first
quarter, including net product sales of $162.0 million. Net loss for the
quarter ended March 31, 2007 was $49.4 million, or $0.38 per share. At March
31, 2007, the Company held cash, cash equivalents and short-term i... |
| | | 04/09/07 | Amylin Pharmaceuticals to Webcast First Quarter Results| SAN DIEGO, April 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first
quarter of 2007 on Monday, April 16, 2007 at 8:30 a.m. ET/5:30 a.m. PT.
Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead
the call. On the same date premarket, Amylin will release financial results
for the first quarter of 2007.
The call will be webcast live through Amylin's corporate website and a
rec... |
| | | 03/14/07 | Delta Burke to Americans: Let's Talk about Managing Diabetes| - BYETTA(R) Let's Talk campaign features meet-and-greet with experts to help
people manage type 2 diabetes through a more active, healthy lifestyle -
SAN DIEGO and INDIANAPOLIS, March 14 /PRNewswire/ -- Stage, screen and
film actress Delta Burke is leading the BYETTA Let's Talk campaign, sponsored
by Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company
(NYSE: LLY). The BYETTA Let's Talk campaign is designed to educate people with
type 2 diabetes about the importance... |
| | | 03/13/07 | Amylin Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference| SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Lehman Brothers Global Healthcare
Conference on Monday, March 19, 2007 at 11:15 a.m. ET in Miami. Mark G.
Foletta, Senior Vice President, Finance and Chief Financial Officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The web... |
| | | 03/08/07 | Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference| SAN DIEGO, March 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Cowen and Company 27th Annual Health
Care Conference on Wednesday, March 14, 2007 at 10:15 a.m. ET in Boston.
Daniel M. Bradbury, President and Chief Executive Officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcast and... |
| | | 03/06/07 | Amylin Pharmaceuticals Elects Teresa Beck to Board of Directors| SAN DIEGO, March 6, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Teresa Beck has been elected to the
company's Board of Directors effective immediately. Ms. Beck will serve on
Amylin's Audit Committee.
"We are very pleased to welcome Teresa to the Amylin Board," said Daniel
M. Bradbury, President and CEO of Amylin Pharmaceuticals. "Her operational
expertise, financial acumen, and retail experience will make her a ... |
| | | 02/20/07 | New Storage Instructions Approved for BYETTA(R)| Refrigeration No Longer Required After First Use
SAN DIEGO and INDIANAPOLIS, Feb. 20 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
announced today that the U.S. Food and Drug Administration (FDA) has approved
more convenient patient storage instructions for BYETTA(R) (exenatide)
injection. BYETTA Pens can now be kept at a room temperature not to exceed 77
degrees F (25 degrees C) after first use.
With the upd... |
| | | 02/06/07 | Amylin Pharmaceuticals Appoints Marcea Bland Lloyd Senior Vice President and General Counsel| Lloyd to Establish Corporate Affairs Organization
SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Marcea Bland Lloyd has been appointed
Senior Vice President, Legal and Corporate Affairs, and General Counsel.
Ms. Lloyd comes to Amylin from VHA, Inc., most recently serving as Group
Senior Vice President, Chief Administrative Officer, General Counsel and
Secretary, where she provided strategic and operational leade... |
| | | 01/31/07 | Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference| SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Merrill Lynch Global Pharmaceutical,
Biotechnology and Medical Device Conference on Tuesday, February 6, 2007 at
9:20 a.m. ET in New York. Daniel M. Bradbury, President and Chief Operating
Officer of Amylin Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available followi... |
| | | 01/30/07 | Amylin Pharmaceuticals Announces Appointment of Daniel M. Bradbury as Chief Executive Officer Effective March 1, 2007| SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Daniel M. Bradbury will become President
and Chief Executive Officer on March 1, 2007. He will succeed Ginger L.
Graham, who has led the company since 2003.
"I've had the pleasure of working with Dan for more than eleven years,
first as a board member and then as a member of the management team. Dan has
a deep appreciation for the two critical elements required to build a... |
| | | 01/30/07 | Amylin Pharmaceuticals Reports 2006 Financial Results| Over $500 Million in Total Revenue Reported in 2006
SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter and year ended
December 31, 2006. The Company reported total revenue of $163.4 million for
the quarter ended December 31, 2006, which includes net product sales of
$150.6 million. Net loss was $58.4 million ($0.45 per share) for the quarter
ended December 31, 2006, which includes $13.9... |
| | | 01/23/07 | Amylin Pharmaceuticals to Webcast Year-End Results| SAN DIEGO, Jan. 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
fourth quarter and full year 2006 on Tuesday, January 30, 2007 at
5:00 p.m. ET/2:00 p.m. PT. Ginger L. Graham, Amylin's Chief Executive Officer,
will lead the call. On the same date, at the close of market, Amylin will
release financial results for the fourth quarter and year ended
December 31, 2006.
The call will be webcast live throu... |
| | | 01/03/07 | FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use| Millions of People Using Thiazolidinediones Now Have New Treatment Option to
Manage Type 2 Diabetes
SAN DIEGO and INDIANAPOLIS, Dec. 22 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
announced today that the U.S. Food and Drug Administration (FDA) has approved
BYETTA(R) (exenatide) injection as an add-on therapy to improve blood sugar
control in people with type 2 diabetes who have not achieved ade... |
| | | 01/02/07 | Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference| SAN DIEGO, Jan. 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the JPMorgan Healthcare Conference on
Monday, January 8, 2007 at 11:30 a.m. PT in San Francisco, CA. Ginger L.
Graham, Chief Executive Officer of Amylin Pharmaceuticals, will be providing a
corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcast and
recording will be accessibl... |
| | | 12/22/06 | FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use| Millions of People Using Thiazolidinediones Now Have New Treatment Option to
Manage Type 2 Diabetes
SAN DIEGO and INDIANAPOLIS, Dec. 22 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
announced today that the U.S. Food and Drug Administration (FDA) has approved
BYETTA(R) (exenatide) injection as an add-on therapy to improve blood sugar
control in people with type 2 diabetes who have not achieved ad... |
| | | 11/24/06 | Amylin Pharmaceuticals to Present at Piper Jaffray Healthcare Conference| SAN DIEGO, Nov 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Piper Jaffray Healthcare Conference
on Friday, December 1, 2006 at 12:00 p.m. ET in New York. Mark G. Foletta,
Senior Vice President, Finance and Chief Financial Officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the... |
| | | 11/21/06 | BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission| - Exenatide is the first in a new class of medicines known as incretin mimetics - INDIANAPOLIS, and SAN DIEGO, Nov 21, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly
and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today
announced that the European Commission has granted marketing authorization for
BYETTA(R) (exenatide) for the treatment of type 2 diabetes. The approval
decision follows a positive opinion adopted September 21, 2006, by the
Commi... |
| | | 11/09/06 | Amylin Pharmaceuticals to Present at BIOCOM Investor Conference and Credit Suisse Healthcare Conference| SAN DIEGO, Nov 09, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the BIOCOM Investor Conference on
Wednesday, November 15, 2006 at 9:00 a.m. PT in San Diego, CA and at the
Credit Suisse Healthcare Conference on Thursday, November 16, 2006 at
11:00 a.m. MT in Phoenix, AZ. Mark G. Foletta, Senior Vice President, Finance
and Chief Financial Officer of Amylin Pharmaceuticals, will be providing a
corporate overview at B... |
| | | 11/01/06 | Amylin Pharmaceuticals to Present at Cowen and Company Global Health Care Conference| SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Cowen and Company 7th Annual Global
Health Care Conference on Tuesday, November 7, 2006 at 9:30 a.m. PT / 5:30
p.m. UKT in London. Berthold Lensker, PhD, Executive Director, European
Operations of Amylin Pharmaceuticals will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following ... |
| | | 10/24/06 | Amylin Pharmaceuticals Expands Clinical Program in Obesity| Five Obesity Studies Announced at Inaugural Research and Development Breakfast
NEW YORK, Oct. 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced an extensive program of clinical trials which
will assess the safety and efficacy of multiple neurohormones used in
combination to treat obesity.
This integrated approach to obesity therapy is based on extensive clinical
experience with the analog of the human hormone, amylin, called pramlintide,
an... |
| | | 10/20/06 | Amylin Pharmaceuticals to Present at First Annual Research & Development Breakfast| SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at its first annual Research & Development
Breakfast on Tuesday, October 24, 2006 at 7:30 a.m. ET at the Grand Hyatt
Hotel in New York.
"Amylin's approach to discovering first-in-class medicines is yielding
exciting results. At our first-ever Research and Development event, we will
share our progress and plans," said Ginger L. Graham, Chief Executive Officer
of Amylin Pharm... |
| | | 10/18/06 | Amylin Pharmaceuticals Reports Third Quarter Financial Results| Net Product Sales Increased 28% Over Prior Quarter to $139 Million
SAN DIEGO, Oct. 18 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter and the nine
months ended September 30, 2006. The Company reported total revenue of
$147 million for the third quarter, which includes net product sales of
$138.8 million. Net loss was $46.1 million ($0.36 per share) for the third
quarter, which includes $14.6 million ($0.12 p... |
| | | 10/12/06 | Amylin Pharmaceuticals to Webcast Third Quarter Results| SAN DIEGO, Oct. 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the third
quarter of 2006 on Wednesday, October 18, 2006 at 5:00 p.m. ET/2:00 p.m PT.
Ginger L. Graham, Amylin's Chief Executive Officer, will lead the call. On
the same date, at the close of market, Amylin will release financial results
for the third quarter ended September 30, 2006.
The call will be webcast live through Amylin's corpora... |
| | | 10/03/06 | Amylin Pharmaceuticals Appoints Joe Young Sr. Vice President, Marketing| SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) announced today that Joe A. Young has been appointed Sr. Vice
President, Marketing. Mr. Young brings a breadth of experience across
multiple commercial roles, including new product planning, product launches,
brand management, sales and sales management. His last 10 years have been
focused on diabetes and other metabolic diseases, with leadership roles in the
commercialization of thiazolidinedione... |
| | | 09/22/06 | Amylin Pharmaceuticals to Present at UBS Warburg Global Life Science Conference| SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the UBS Warburg Global Life Science
Conference on Wednesday, September 27, 2006 at 7:30 a.m. ET in New York.
Daniel Bradbury, President and Chief Operating Officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcast and
recor... |
| | | 09/21/06 | Exenatide Receives Positive Opinion From the European Committee for Medicinal Products for Human Use for the Treatment of Type 2 Diabetes| - The first medicine in a new class of treatments known as incretin mimetics -
INDIANAPOLIS and SAN DIEGO, Sept. 21 /PRNewswire-FirstCall/ -- Eli Lilly
and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today
announced that the Committee for Medicinal Products for Human Use (CHMP) of
the European Medicines Evaluation Agency (EMEA) has issued a positive opinion
recommending approval of exenatide for the treatment of type 2 diabetes. If
approved, this new medicine fo... |
| | | 09/16/06 | New study shows exenatide improves blood sugar levels as effectively | Patients taking exenatide lost weight while patients taking insulin glargine gained weight
COPENHAGEN, DENMARK, SEPTEMBER 16, 2006 - Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) today announced results from a study indicating that exenatide improves blood sugar levels as effectively as insulin glargine (Lantus®, Sanofi Aventis) for people with type 2 diabetes failing to achieve acceptable blood sugar control on metformin or a sulfonylurea, two common oral ... |
| | | 09/15/06 | Amylin Pharmaceuticals to Present at Nordea Novel Anti-Diabetics Seminar, Oppenheimer Diabetes Conference and Merrill Lynch Global Conference| SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at three upcoming conferences. A corporate
overview will be provided by Berthold Lensker, PhD, Executive Director,
European Operations of Amylin Pharmaceuticals and a clinical overview will be
provided by David Kendall, MD, Executive Director, Medical Affairs of Amylin
Pharmaceuticals at the Nordea Novel Anti-diabetics Seminar on Tuesday,
September 19, 2006 at 4:30 a.m. PT / 1:... |
| | | 09/14/06 | Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart| - Patients on exenatide lost weight, while insulin aspart patients
gained weight -
COPENHAGEN, Denmark, Sept. 14 /PRNewswire-FirstCall/ -- Eli Lilly and
Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today
announced results from a study indicating that exenatide improves blood sugar
levels as effectively as biphasic insulin aspart 30/70 (NovoMix 30(R),
NovoNordisk) for people with type 2 diabetes failing to achieve acceptable
b... |
| | | 09/14/06 | Study demonstrated once-weekly exenatide LAR improved glucose control in patients with type 2 diabetes| COPENHAGEN, DENMARK - Eli Lilly and Company (NYSE: LLY), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), and Alkermes, Inc. (Nasdaq: ALKS) today announced detailed results from a safety and efficacy study of the long-acting release (LAR) formulation of exenatide. Data from the study demonstrated that 86 percent of patients using the higher of two doses of the once-weekly formulation of exenatide were able to achieve recommended levels of glucose control, as measured by hemoglobin A1C (HbA1C) with a... |
| | | 09/07/06 | SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes on Established Regimens of Basal Insulin| SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced positive results from a 16-week study
evaluating the safety and efficacy of adding SYMLIN(R) (pramlintide acetate)
to an established regimen of basal insulin glargine (with or without oral
antidiabetic agents) in patients with type 2 diabetes who have not progressed
to mealtime insulin therapy. At study end, patients receiving SYMLIN on
average had better overall glucose control (A... |
| | | 09/01/06 | Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference| SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the BioCentury NewsMakers Conference on
Thursday, September 7, 2006 at 9:00 a.m. ET in New York, at the Thomas Weisel
Healthcare Conference on Friday, September 8, 2006 at 11:30 a.m. ET in Boston
and at the Bear Stearns Healthcare Conference on Monday, September 11, 2006 at
8:00 a.m. ET in New York. Ginger L. Graham, Chief Executive Officer of Amylin
Pharmaceuticals, will be ... |
| | | 08/24/06 | Amylin Pharmaceuticals, Inc. Announces Conversion of All Outstanding 2.25% Convertible Senior Notes Due 2008| SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that in connection with the previously
announced redemption of its 2.25% convertible senior notes due June 30, 2008,
issued in 2003, holders of all of the outstanding notes converted their notes
into shares of Amylin's common stock prior to the August 24, 2006 redemption
date. The aggregate outstanding principal amount of the notes was $175
million. As a result of these conversion... |
| | | 07/24/06 | Amylin Pharmaceuticals Reports Second Quarter Financial Results| Net Product Sales Increased 43% Over Prior Quarter to $109 Million
SAN DIEGO, July 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter and six months
ended June 30, 2006. The Company reported total revenues of $118.1 million
for the second quarter, which includes net product sales of $108.8 million.
Net loss was $46.4 million ($0.38 per share) for the quarter ended June 30,
2006, which includes $12.4 million (... |
| | | 07/24/06 | Amylin Pharmaceuticals, Inc. Announces Details of Redemption of 2.25% Convertible Senior Notes Due June 30, 2008| SAN DIEGO, July 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that it will call for the full redemption on
August 24, 2006 of all of its outstanding 2.25% convertible senior notes due
June 30, 2008 issued in June and July 2003. The notes will be called on July
25, 2006 as a provisional redemption based upon the market price of Amylin
common stock exceeding certain thresholds. The aggregate principal amount
outstanding of the notes is $175 mi... |
| | | 07/21/06 | Amylin Pharmaceuticals Announces BYETTA Revenue| Second Quarter Results and Conference Call Scheduled for July 24
SAN DIEGO, July 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that unaudited net product sales for BYETTA(R)
(exenatide) injection for the quarter ended June 30, 2006 were $98.6 million.
These net product sales are being released in conjunction with today's
financial results announced by Eli Lilly and Company, Amylin's collaboration
partner for BYETTA.
Conference Call... |
| | | 07/17/06 | Amylin Pharmaceuticals to Webcast Second Quarter Results| SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
second quarter of 2006 on Monday, July 24, 2006 at 5:00 p.m. ET/2:00 p.m PT.
Ginger L. Graham, Amylin's Chief Executive Officer, will lead the call. On
the same date, at the close of market, Amylin will release financial results
for the second quarter ended June 30, 2006.
The call will be webcast live through Amylin's corporate website ... |
| | | 06/20/06 | Amylin Pharmaceuticals to Present at William Blair Growth Stock Conference and Piper Jaffray European Healthcare Conference| SAN DIEGO, June 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Piper Jaffray European Healthcare
Conference on Friday, June 23, 2006 at 1:20 a.m. PT / 9:20 a.m. GMT in London,
UK and at the William Blair Growth Stock Conference on Thursday, June 29, 2006
at 11:10 a.m. CT in Chicago, IL. Berthold Lensker, PhD, Executive Director,
European Operations of Amylin Pharmaceuticals, will be presenting at the Piper
Jaffray conference. Ginger... |
| | | 06/10/06 | BYETTA(R) Shown to Reduce Blood Glucose Levels When Added to Patients Using a TZD| Most patients saw improvements in three critical measures
of blood glucose control
WASHINGTON, D.C., June 10 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced detailed findings from a study that showed BYETTA(R)
(exenatide) injection lowered blood glucose levels for people with type 2
diabetes who had not achieved target blood glucose levels despite the use of a
thiazolidined... |
| | | 06/10/06 | Late Breaking Data at ADA 2006 Shows Amylin-Leptin Co-Administration Reduces Body Weight and Body Fat in Animal Studies| WASHINGTON, June 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced study results showing that co-administration of
two neurohormones known to have a role in body weight control, amylin
(produced by beta cells in the pancreas) and leptin (produced by fat cells),
resulted in sustained, fat-specific weight loss in a leptin-resistant animal
model of obesity.
These findings were presented at the 66th Annual Scientific Sessions of
the American Diab... |
| | | 06/10/06 | BYETTA(R) Extension Study Shows Sustained Improvements in Blood Glucose Control and Progressive Weight Loss After Two Years| WASHINGTON, D.C., June 10 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced two-year study results showing that BYETTA(R) (exenatide)
injection sustained improvements in blood sugar control and reduced body
weight in people with type 2 diabetes who previously did not achieve adequate
control of their blood sugar on common oral medications. These findings were
presented at the 66th Annual Scientific Sessions of t... |
| | | 06/10/06 | Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes| WASHINGTON, D.C., June 10 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and
Alkermes, Inc. (Nasdaq: ALKS) today announced detailed results from a safety
and efficacy study of the long-acting release (LAR) formulation of BYETTA(R)
(exenatide) injection. Data from the study demonstrated that 86 percent of
patients using the higher of two doses of the once-weekly formulation of
exenatide were able to achieve recommended levels of ... |
| | | 06/10/06 | New Study Illustrates Economic Benefit of Weight Loss in People with Type 2 Diabetes| WASHINGTON, DC June 10, 2006 - A new study demonstrated that even a small percentage of weight loss could lower health care costs among people with type 2 diabetes. Data from the study, titled "Short Term Economic Impact of Weight Change Among Patients with Type 2 Diabetes," were presented today at the 66th Annual Scientific Sessions of the American Diabetes Association (ADA) in Washington, DC. The study was funded by an unrestricted research grant from Amylin Pharmaceuticals, Inc. and Eli Lilly... |
| | | 06/09/06 | Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference| SAN DIEGO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Goldman Sachs Global Healthcare
Conference on Wednesday, June 14, 2006 at 9:20 a.m. PT in Laguna Nigel, CA.
Mark G. Foletta, Senior Vice President, Finance and Chief Financial Officer of
Amylin Pharmaceuticals, will be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recor... |
| | | 06/07/06 | Amylin Pharmaceuticals Promotes Daniel M. Bradbury to President and Chief Operating Officer| Bradbury Also Appointed to the Board of Directors
SAN DIEGO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Daniel M. Bradbury has been promoted to
President and Chief Operating Officer. Bradbury was also appointed to
Amylin's Board of Directors and as part of the company's succession plan, will
become Chief Executive Officer within a year.
"Amylin has evolved from a research and development organization to a
commer... |
| | | 06/06/06 | Amylin Pharmaceuticals Demonstrates Progress Across Diabetes and Obesity Portfolios at ADA 2006| Data Disclosure Through Company-Sponsored WebcastSAN DIEGO, June 6, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that data featuring its approved drugs and
pipeline candidates will be presented at the 66th Annual Scientific Sessions
of the American Diabetes Association (ADA) being held in Washington, DC from
June 9 to 13. The company will also host an investor conference during the
meeting that will be available by webca... |
| | | 05/25/06 | Amylin Pharmaceuticals to Present at Friedman Billings Ramsey Growth Conference| SAN DIEGO, May 25 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Friedman Billings Ramsey Growth
Conference on Thursday, June 1, 2006 at 8:15 a.m. ET in New York, NY. Ginger
Graham, President and Chief Executive Officer of Amylin Pharmaceuticals, will
be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
thr... |
| | | 05/10/06 | Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders and Bank of America Health Care Conference| SAN DIEGO, May 10, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast their Annual Meeting of Stockholders on Wednesday,
May 17, 2006 at 10:00 a.m. Pacific Time from the company's corporate
headquarters in San Diego, CA. Following the Annual Meeting, Ginger L.
Graham, President and Chief Executive Officer of Amylin Pharmaceuticals, will
be providing a corporate overview.
Amylin will also be presenting at the Bank of America He... |
| | | 05/01/06 | Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference| SAN DIEGO, May 1, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Morgan Stanley Global Healthcare
Unplugged Conference on Friday, May 5, 2006 at 9:30 a.m. ET in Miami, FL.
Daniel Bradbury, Chief Operating Officer of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be ... |
| | | 04/26/06 | Amylin Pharmaceuticals Reports First Quarter Financial Results| First Quarter Net Product Sales Increase to $76 Million
SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the first quarter ended
March 31, 2006. The Company reported total revenue of $82.3 million for the
first quarter, including net product sales of $75.9 million. Net loss for the
quarter ended March 31, 2006 was $67.9 million, or $0.61 per share. Pro forma
net loss for the quarter ended March ... |
| | | 04/20/06 | Amylin Pharmaceuticals Announces BYETTA Revenue| First Quarter Results and Conference Call Scheduled for April 26
SAN DIEGO, April 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that unaudited net product sales for BYETTA(R)
(exenatide) injection for the quarter ended March 31, 2006 were approximately
$68 million. BYETTA net product sales consist of shipments to the Company's
wholesale customers, net of allowances for prescription coupons, payor
discounts, distribution fees and return... |
| | | 04/04/06 | Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters| SAN DIEGO, April 4, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced the exercise by its underwriters of an
over-allotment option to purchase 1,500,000 shares of common stock associated
with its follow-on stock offering that priced on March 29, 2006. Including
the over-allotment shares, the offering will total 11,500,000 shares at $46.50
per share, resulting in expected net proceeds to the company of approximately
$508 mill... |
| | | 03/30/06 | Amylin Pharmaceuticals Announces Public Offering of Common Stock| SAN DIEGO, March 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced a public offering of 10,000,000 shares of
common stock at a price of $46.50 per share, resulting in estimated net
proceeds to Amylin of approximately $441.4 million. The Company has granted
to the underwriters an option to purchase up to 1,500,000 additional shares of
common stock from the company to cover over-allotments, if any, within 30 days
from the date of the prospectus sup... |
| | | 03/28/06 | Amylin Pharmaceuticals Elects Steven Altman to Board of Directors| SAN DIEGO, March 28 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Steven R. Altman has been elected to the
company's Board of Directors effective immediately. Mr. Altman will serve on
Amylin's Compensation and Human Resources Committee.
"We are very pleased to welcome Steve to the Amylin Board," said Ginger L.
Graham, President and CEO of Amylin Pharmaceuticals. "He helps lead QUALCOMM
Incorporated, a large, global technology business ... |
| | | 03/27/06 | Amylin Pharmaceuticals Announces Public Offering of Common Stock| SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) today announced that it has filed a preliminary prospectus supplement to a shelf registration statement with the Securities and Exchange Commission relating to a proposed public offering of 8,500,000 shares of its common stock. The underwriters will be granted the right to purchase up to an additional 1,275,000 shares of common stock to cover over-allotments, if any. All of the shares are being sold... |
| | | 03/24/06 | Once-Weekly Exenatide LAR Clinical Study in Type 2 Diabetes Initiated| SAN DIEGO, CA, INDIANAPOLIS, IN and CAMBRIDGE, MA, March 24
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli
Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today
announced that, following discussions with the U.S. Food and Drug
Administration (FDA), a long-term comparator clinical study of a long-acting
release (LAR) formulation of BYETTA(R) (exenatide) injection in patients with
type 2 diabetes has been initiated. This study is designed to g... |
| | | 03/02/06 | Amylin Pharmaceuticals to Present at Cowen & Co. Health Care Conference and Lehman Brothers Global Healthcare Conference| SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Cowen & Co. Health Care Conference on
Wednesday, March 8, 2006 at 2:30 p.m. ET in Boston and at the Lehman Brothers
Global Healthcare Conference on Thursday, March 9, 2006 at 8:00 a.m. ET in
Miami Beach, FL. Ginger Graham, President and Chief Executive Officer of
Amylin Pharmaceuticals, will be providing a corporate overview at both
conferences.
The live presentation... |
| | | 03/01/06 | Supplemental New Drug Application for BYETTA Submitted to FDA for Use With TZDs| SAN DIEGO and INDIANAPOLIS, March 1 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
announced the recent submission of a supplemental New Drug Application to the
Food and Drug Administration (FDA) to seek approval for expanded use of
BYETTA(R) (exenatide) injection as add-on therapy to a common class of oral
diabetes medication called thiazolidinediones (or TZDs), in people with type 2
diabetes who are not achieving acceptable... |
| | | 02/22/06 | Amylin Pharmaceuticals to Present at Citigroup Healthcare Conference| SAN DIEGO, Feb. 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Citigroup Healthcare Conference on
Tuesday, February 28, 2006 at 8:35 a.m. ET in Washington, DC. Mark Foletta,
VP, Finance and Chief Financial Officer of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
throug... |
| | | 02/09/06 | Pramlintide Obesity Study Results Positive| Phase 2 Dose-Ranging Study Complete
SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced positive results from a 16-week Phase 2
dose-ranging study evaluating the safety and weight effects of pramlintide in
obese subjects. Average weight loss across the pramlintide treatment groups
ranged from 8.4 to 13.4 pounds from baseline, compared to 6.2 pounds for the
placebo group. Both twice-daily and three-times-a-day re... |
| | | 02/09/06 | Amylin Pharmaceuticals Reports 2005 Financial Results| Fourth Quarter Net Product Sales Increase to $56 Million
SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter and year ended
December 31, 2005. The Company reported total revenue of $63.5 million for
the fourth quarter, including net product sales of $56.2 million. The net
loss for the quarter ended December 31, 2005 was $67.2 million, or $0.61 per
share. At December 31, 2005, the Company ... |
| | | 02/02/06 | Amylin Pharmaceuticals to Webcast Year-End Results| SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
fourth quarter of 2005 on Thursday, February 9, 2006 at 5:00 p.m. ET/
2:00 p.m. PT. Ginger L. Graham, Amylin's President and Chief Executive
Officer will lead the call. On the same date, at the close of market, Amylin
will release financial results for the fourth quarter and fiscal year ended
December 31, 2005.
For those without access... |
| | | 01/26/06 | Amylin Pharmaceuticals Announces BYETTA Revenue| Preliminary Fourth Quarter 2005 Results
SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that unaudited net product sales for BYETTA(R)
(exenatide) injection for the quarter ended December 31, 2005 were
approximately $49 million. BYETTA net product sales consist of shipments to
the Company's wholesale customers, net of allowances for discounts,
distribution fees and returns. These preliminary results are being... |
| | | 01/09/06 | Amylin Pharmaceuticals Added to the NASDAQ-100 Index| SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) announced that, effective today, it has been added to the
NASDAQ-100 Index(R), which is composed of the 100 largest non-financial stocks
on The NASDAQ Stock Market(R) based on market capitalization and eligibility
criteria.
"We are pleased to be included on the NASDAQ-100 Index and listed among
the top companies in the world," said Ginger L. Graham, President and CEO of
Amylin Pharmaceuticals, ... |
| | | 01/03/06 | Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference| SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the JPMorgan Healthcare Conference on
Monday, January 9, 2006 at 9:00 AM PT in San Francisco. Ginger L. Graham,
Chief Executive Officer of Amylin Pharmaceuticals, will be providing a
corporate overview.
The live presentation and breakout session will be webcast, and recordings
will be made available following the event. The webcasts and recordings will
be accessible thro... |
| | | 12/29/05 | Amylin Pharmaceuticals Acquires Facility in Ohio to Manufacture Exenatide LAR| SAN DIEGO, Dec. 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that it has purchased an existing 150,000
square foot building and 26 acres of land in West Chester, Ohio. This
acquisition completes previously announced facility expansion plans for the
eventual commercial manufacturing of a long-acting release (LAR) formulation
of exenatide, a product candidate in development for the treatment of type 2
diabetes. Exenatide is the active ingredi... |
| | | 12/22/05 | Amylin Recognized for Biotechnology Leadership and Product Innovation| SAN DIEGO, Dec. 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) is honored to be recognized with three prestigious awards for
biotechnology excellence, product innovation, and leadership. Earlier this
month, Amylin won the inaugural Scrip Award for Biotechnology Company of the
Year. In addition, SYMLIN(R) (pramlintide acetate) injection won the CONNECT
Award for Most Innovative New Product in the area of Life Science
Therapeutics, and earlier this year Ginger... |
| | | 12/21/05 | Amylin Pharmaceuticals Elects Dr. James Gavin to Board of Directors| SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Dr. James R. Gavin III was elected to the
company's Board of Directors on December 16. Dr. Gavin will serve on Amylin's
Nominating and Governance Committee.
"We're thrilled to welcome Dr. Gavin to the Amylin Board," said Ginger L.
Graham, President and CEO of Amylin Pharmaceuticals. "His extensive diabetes
knowledge, distinguished academic career, and substantial board an... |
| | | 11/15/05 | BYETTA Shown to Reduce Blood Sugar Levels When Added to Patients Treated With TZDs| - More Than 60 Percent of Patients Achieved A1C Treatment Goal -
SAN DIEGO and INDIANAPOLIS, Nov. 15 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced positive results from a study of BYETTA(R) (exenatide)
injection used in addition to a common class of oral diabetes medication
called thiazolidinediones (or TZDs), in people with type 2 diabetes who were
not achieving acceptable blood sugar control. Resul... |
| | | 11/10/05 | Amylin Pharmaceuticals to Present at Lehman Brothers Small Cap Conference| SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Lehman Brothers Small Cap Conference
on Thursday, November 17, 2005 at 2:15 p.m. PT in Carlsbad, California.
Daniel M. Bradbury, Chief Operating Officer of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation and breakout session will be webcast, and recordings
will be made available following the event. The webcasts and recordings wil... |
| | | 10/26/05 | Amylin Pharmaceuticals Reports Third Quarter Financial Results| Net Product Sales Increase to ~$22 Million in First Full Quarter of
Commercialization
SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter and the nine
months ended September 30, 2005. The Company reported total revenue of
$25.9 million for the third quarter, the first full quarter of commercial
operations, including net product sales of $21.9 million. The net loss ... |
| | | 10/20/05 | Amylin Pharmaceuticals to Webcast Third Quarter Results| SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the third
quarter of 2005 on Wednesday, October 26, 2005 at 5:00 p.m. ET/2:00 p.m. PT.
Ginger L. Graham, Amylin's President and Chief Executive Officer will lead the
call. On the same date, at the close of market, Amylin will release financial
results for the third quarter ended September 30, 2005.
For those without access to the Internet, ... |
| | | 09/28/05 | Amylin Pharmaceuticals Elects Karin Eastham to Board of Directors| SAN DIEGO, Sept 28, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Karin Eastham has been elected to the
company's board of directors effective immediately. Ms. Eastham will serve on
Amylin's audit committee.
"We are very excited to welcome Karin to the Amylin team," said Ginger L.
Graham, President and CEO of Amylin Pharmaceuticals. "Her extensive financial
and operations management experience in the life sciences ... |
| | | 09/22/05 | Amylin Pharmaceuticals to Present at UBS Global Life Sciences Conference| SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the UBS Global Life Sciences Conference
on Tuesday, September 27, 2005 at 8:00 a.m. ET in New York. Daniel M.
Bradbury, Chief Operating Officer of Amylin Pharmaceuticals, will be providing
a corporate overview.
The live presentation and breakout session will be webcast, and recordings
will be made available following the event. The webcasts and recordings will
be acces... |
| | | 09/19/05 | Amylin Pharmaceuticals Appoints Roger Marchetti as Senior Vice President of Human Resources and Corporate Services| SAN DIEGO, Sept. 19 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Roger Marchetti will join the Company as
Senior Vice President, Human Resources and Corporate Services. Mr. Marchetti
will take over for Martin Brown, who will be retiring from Amylin in October.
"We are very excited to welcome Roger to the Amylin team," said Ginger L.
Graham, President and CEO of Amylin Pharmaceuticals. "His leadership and
experience in the healthcare i... |
| | | 09/12/05 | Long-term data on exenatide show sustained improvements in glucose control and progressive weight reduction in people with type 2 diabetes| -- Improvements in cardiovascular risk factors were also observed--
ATHENS, GREECE, 12 September 2005 - Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) today presented results from a study indicating that the investigational compound exenatide showed sustained improvements in blood sugar control and progressive weight reduction through two years of therapy for people with type 2 diabetes failing to achieve acceptable blood sugar control on metformin and/or a ... |
| | | 09/12/05 | Study shows exenatide improves blood sugar levels | -- Patients on exenatide also lost weight, while glargine patients gained weight --
ATHENS, GREECE, 12 September 2005 - Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) today announced results from a study indicating that exenatide improves blood sugar levels as effectively as insulin glargine (Lantus®, Sanofi-Aventis) for people with type 2 diabetes failing to achieve acceptable blood sugar control on both metformin and a sulfonylurea, two common oral diabe... |
| | | 09/09/05 | Amylin Pharmaceuticals to Present at Bear Stearns Healthcare Conference| SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Bear Stearns Healthcare Conference on
Tuesday, September 13, 2005 at 8:00 a.m. ET in New York. Mark G. Foletta, VP,
Finance and Chief Financial Officer of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation and breakout session will be webcast, and recordings
will be made available following the event. The webcasts and recordings will
... |
| | | 09/02/05 | Amylin Pharmaceuticals to Present at Oppenheimer Diabetes Conference, Thomas Weisel Healthcare Tailwinds Conference and Biocentury Newsmakers Conference| SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Oppenheimer Diabetes Conference on
Wednesday, September 7, 2005 at 9:35 a.m. ET in New York, at the Thomas Weisel
Healthcare Tailwinds Conference on Thursday, September 8, 2005 at 9:45 a.m. ET
in Boston and at the BioCentury Newsmakers Conference on Friday, September 9,
2005 at 10:00 a.m. ET in New York. Dennis Kim, Senior Director, Medical
Affairs of Amylin Pharmaceuticals, ... |
| | | 08/30/05 | Amylin Pharmaceuticals Announces Public Offering of Common Stock| SAN DIEGO, Aug 30, 2005 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced a public offering of 5,068,138 shares of common
stock at a price of $31.00 per share under shelf registration statements
previously filed and declared effective by the Securities and Exchange
Commission (SEC). Net proceeds to Amylin are expected to be approximately
$152 million.
A prospectus supplement relating to the offering will be filed with the
SEC by Amylin, ... |
| | | 08/22/05 | Once Weekly Exenatide LAR Well Tolerated and Improved Glucose Control| - Preliminary Results From Phase 2 Study Announced -
SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 22
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli
Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today
announced results from the ongoing Phase 2 multi-dose study of a long-acting
release (LAR) formulation of BYETTA(TM) (exenatide) injection in patients with
type 2 diabetes.
The study was designed to assess the safety, tolerabili... |
| | | 08/04/05 | Amylin Pharmaceuticals Reports Second Quarter Financial Results| Company Records First Product Sales Following Launch of Two First-in-Class
Diabetes Medicines in the Second Quarter
SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter and the six
months ended June 30, 2005. The Company reported total revenue of
$46.8 million for the second quarter, which included the Company's first net
product sales of $8.7 million. Net loss was $26.6 million o... |
| | | 07/29/05 | Amylin Pharmaceuticals to Webcast Second Quarter Results| SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
second quarter of 2005 on Thursday, August 4, 2005 at 5:00 p.m. ET/2:00 p.m.
PT. The call will be led by Ginger L. Graham, Amylin's President and Chief
Executive Officer. On the same date, at the close of market, Amylin will
release financial results for the second quarter ended June 30, 2005.
For those without access to the Internet, th... |
| | | 06/23/05 | Amylin Pharmaceuticals to Present at Bear Stearns Boston Biotech Confab and Friedman Billings Ramsey European Investor Conference| SAN DIEGO, June 23, 2005 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Bear Stearns Boston Biotech Confab on
Tuesday, June 28, 2005 at 8:00 a.m. ET in Boston and at the Friedman Billings
Ramsey European Investor Conference on Wednesday, June 29, 2005 at 3:30 p.m.
GMT in London. Ginger L. Graham, President and Chief Executive Officer of
Amylin Pharmaceuticals, will be providing a corporate overview at the Bear
Stearns Confab. Be... |
| | | 06/10/05 | Long-Term Data on BYETTA(TM) Show Sustained Improvements in Glucose Control and Progressive Weight Reduction in People with Type 2 Diabetes| -- Improvements in cardiovascular risk factors were also observed --
SAN DIEGO, June 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.,
(Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results
from a study indicating that BYETTA(TM) (exenatide) injection showed sustained
improvements in blood sugar control and progressive weight reduction through a
year and a half of therapy for people with type 2 diabetes failing to achieve
acceptable blood sugar control ... |
| | | 06/10/05 | Study Shows BYETTA(TM) Improves Blood Sugar Levels as Effectively as Insulin Glargine| -- Patients on BYETTA also lost weight, while glargine patients
gained weight --
SAN DIEGO, June 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.,
(Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results
from a study indicating that BYETTA(TM) (exenatide) injection improves blood
sugar levels as effectively as insulin glargine (Lantus(R), Sanofi-Aventis)
for people with type 2 diabetes failing to achieve acceptable blood sug... |
| | | 06/09/05 | Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference| SAN DIEGO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Goldman Sachs Global Healthcare
Conference on Wednesday, June 15, 2005 at 11:00 a.m. PT in Dana Point, CA.
Ginger L. Graham, Chief Executive Officer of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
through Amyl... |
| | | 06/09/05 | Newly Approved First-in-Class Treatment for Type 2 Diabetes Is Now Available|
-- Amylin and Lilly Launch BYETTA(TM) (exenatide) injection for
type 2 diabetes patients unable to control disease with common
oral therapies --
SAN DIEGO, and INDIANAPOLIS, June 9 /PRNewswire-FirstCall/ -- BYETTA(TM)
(exenatide) injection is now available for Americans struggling to control
their type 2 diabetes. BYETTA can help diabetes patients manage blood sugar
while potentially losing weight. Recently approved by the Food and D... |
| | | 06/06/05 | Amylin Pharmaceuticals Announces Presentation of 12 Abstracts at the American Diabetes Association Annual Meeting| Data Disclosure through Company-Sponsored Webcast
SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that data featuring its two recently approved
diabetes drugs, BYETTA(TM) (exenatide) injection and SYMLIN(R) (pramlintide
acetate) injection, will be presented at the 65th Annual Scientific Sessions
of the American Diabetes Association (ADA) being held in San Diego, California
from June 10 - 14, 2005. The meeting is one of the larg... |
| | | 06/03/05 | Amylin Presents Results From Pramlintide Obesity Program at 14th Annual European Congress on Obesity| New Dose-Ranging Study Enrolling
SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today presented detailed data from a 16-week Phase 2 obesity
study of pramlintide (AC137) at the European Congress on Obesity (ECO) in
Athens, Greece. Pramlintide is a synthetic analog of human amylin, a hormone
known to play a role in the regulation of appetite and food intake. The study
showed statistically significant, progressive weight loss of 3.6 percent
(... |
| | | 05/20/05 | Amylin Pharmaceuticals to Webcast Annual Meeting of Stockholders and Presentation| SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast their Annual Meeting of Stockholders on
Wednesday, May 25, 2005 at 10:00 a.m. Pacific Time from the company's
corporate headquarters in San Diego, CA. Following the Annual Meeting, Ginger
Graham, President and Chief Executive Officer of Amylin Pharmaceuticals, will
be providing a corporate overview, and Dr. Steven Edelman, Professor of
Medicine, Division of Endocrinology & Metabolism, Univ... |
| | | 05/13/05 | Amylin Pharmaceuticals to Present at Banc of America Securities' Health Care Conference| SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Banc of America Securities' Health
Care Conference on Wednesday, May 18, 2005 at 8:00 a.m. PT in Las Vegas.
Daniel M. Bradbury, Chief Operating Officer of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
through Am... |
| | | 05/04/05 | Amylin Pharmaceuticals Reports First Quarter Financial Results| Company Launching Two First-in-Class Diabetes Medicines in Second Quarter
SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported a net loss of $43.6 million, or $0.43 per share,
for the first quarter ended March 31, 2005, compared to a net loss of
$37.3 million, or $0.40 per share, for the same period in 2004. At March 31,
2005, the Company held cash, cash equivalents and short-term investments of
approximately $440 million. The Compan... |
| | | 04/29/05 | Amylin Pharmaceuticals to Webcast First Quarter Results and Morgan Stanley Global Healthcare Unplugged Conference Presentation| SAN DIEGO, April 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first
quarter of 2005 on Wednesday, May 4, 2005 at 12:00 p.m. ET/9:00 a.m. PT. The
call will be led by Ginger L. Graham, Amylin's President and Chief Executive
Officer. On the same date, prior to the market open, Amylin will release
financial results for the first quarter ended March 31, 2004.
For those without access to the Internet, t... |
| | | 04/29/05 | Amylin and Lilly Announce FDA Approval of BYETTA(TM) (Exenatide) Injection| --A New First-in-Class Treatment for Patients with Type 2 Diabetes--
SAN DIEGO, Calif. and INDIANAPOLIS, Ind., April 29 /PRNewswire-FirstCall/
-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), and Eli Lilly and Company
(NYSE: LLY) announce that the U.S. Food and Drug Administration (FDA) has
approved BYETTA(TM) (exenatide) injection as adjunctive therapy to improve
blood sugar control in patients with type 2 diabetes who have not achieved
adequate control on metformin and/or a sulfonylur... |
| | | 03/25/05 | Amylin Pharmaceuticals to Present at Smith Barney Citigroup Healthcare Conference and Lehman Brothers Global Healthcare Conference| SAN DIEGO, March 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Smith Barney Citigroup Healthcare
Conference on Wednesday, March 30, 2005 at 2:30 p.m. ET in Washington D.C. and
at the Lehman Brothers Global Healthcare Conference on Friday, April 1, 2005
at 8:30 a.m. ET in Miami Beach, FL. Mark G. Foletta, Vice President, Finance
and Chief Financial Officer of Amylin Pharmaceuticals, will be providing a
corporate overview... |
| | | 03/16/05 | Amylin Pharmaceuticals Announces FDA Approval of SYMLIN(R) for Insulin-Using Type 2 and Type 1 Diabetes| For Use With Insulin to Improve Glucose Control
SAN DIEGO, March 16 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that the U.S. Food and Drug Administration
(FDA) has approved SYMLIN(R) (pramlintide acetate) injection to be used in
conjunction with insulin to treat diabetes. SYMLIN is to be used at mealtime
in patients with type 2 or type 1 diabetes who have failed to achieve desired
glucose control despite optimal insulin therapy. SYMLIN wil... |
| | | 03/02/05 | Amylin Pharmaceuticals Reports 2004 Financial Results| - 2004 Development Milestones Achieved on Plan - SAN DIEGO, March 2, 2005 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the quarter and year ended
December 31, 2004. The Company reported a net loss of $157.2 million, or
$1.67 per share, for the fiscal year ended December 31, 2004, compared to a
net loss of $122.8 million, or $1.33 per share, for the year ended
December 31, 2003. For the fourth quarter ended December ... |
| | | 02/24/05 | Amylin Pharmaceuticals to Webcast Year-End Results| SAN DIEGO, Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
fourth quarter of 2004 on Wednesday, March 2, 2005 at 12:00 p.m. Eastern/
9:00 a.m. Pacific. The call will be led by Ginger L. Graham, Amylin's
President and Chief Executive Officer. On the same date, prior to the market
open, Amylin will release financial results for the fourth quarter and fiscal
year ended December 31, 2004.
... |
| | | 02/07/05 | Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference| SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Merrill Lynch Global Pharmaceutical,
Biotechnology & Medical Device Conference on Thursday, February 10, 2005 at
9:30 a.m. ET in New York. Daniel Bradbury, Chief Operating Officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording w... |
| | | 01/27/05 | Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters| SAN DIEGO, Jan 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced the exercise by its underwriters of an
over-allotment option to purchase 1,200,000 shares of common stock associated
with its follow-on stock offering which priced on January 20, 2005. Including
the over-allotment shares, the offering will total 9,200,000 shares at $22.00
per share, resulting in expected net proceeds to the company of approximately
$190.5 million.
... |
| | | 01/21/05 | Amylin Pharmaceuticals to Present at Piper Jaffray Health Care Conference| SAN DIEGO, Jan. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Piper Jaffray Health Care Conference
on Wednesday, January 26, 2005 at 10:30 a.m. ET in New York. Mark Foletta,
VP, Finance and Chief Financial Officer of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation and breakout session will both be webcast, and
recordings will be made available following the events. The webcasts and
recording... |
| | | 01/21/05 | Amylin Pharmaceuticals Announces Public Offering of Common Stock| SAN DIEGO, Jan. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced a public offering of 8.0 million shares of
common stock at a price of $22.00 per share. The underwriters have a 30-day
option to purchase up to 1.2 million additional shares of common stock from
the company to cover over-allotments.
Morgan Stanley & Co. Incorporated is acting as the sole book running and
joint lead manager for the offering. Goldman, Sachs & Co. is acting as join... |
| | | 01/18/05 | Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for Public Offering of Common Stock| SAN DIEGO, Jan. 18 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that it has filed a preliminary prospectus
supplement to its shelf registration statement with the Securities and
Exchange Commission relating to a proposed underwritten public offering of
6.5 million shares of its common stock. To the extent that the underwriters
sell more than 6.5 million shares, the company also will grant an over-
allotment option to the underwriters for the purcha... |
| | | 01/05/05 | Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference| SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the JPMorgan Healthcare Conference on
Monday, January 10, 2005 at 9:00 a.m. Pacific Time in San Francisco,
California. Ginger L. Graham, President and Chief Executive Officer of Amylin
Pharmaceuticals will be providing a corporate overview, which will include a
review of the company's development programs. The company will also
participate in a webcast breakout session immediatel... |
| | | 12/05/04 | Amylin Pharmaceuticals Provides Update On Clinical Development Programs| SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today presented an update on its clinical development programs
at a reception webcast from San Diego, CA. Included in the presentation were
new data from its pramlintide (AC137) obesity program and details of a Phase 2
study recently initiated in its AC2592 development program for congestive
heart failure. The successful completion of the AC137 study and initiation of
the AC2592 study mark the achi... |
| | | 12/01/04 | Amylin Pharmaceuticals to Webcast Corporate Update| SAN DIEGO, Dec 1, 2004 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast a corporate update on Sunday, December 5, 2004 at
7:00 p.m. Pacific Time. Ginger L. Graham, President and Chief Executive
Officer of Amylin Pharmaceuticals, and other management team members will
provide a corporate overview and updates on the company's development
programs.
The presentation will be webcast live, and a recording will be made
available following the eve... |
| | | 11/02/04 | Exenatide LAR Data Support Initiation of Phase 2 Multi-Dose Study in 2005| SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Nov. 2,
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli
Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today
announced the decision to initiate a Phase 2 multi-dose study of exenatide LAR
(long-acting release) in patients with type 2 diabetes using a once-a-week
dosing regimen. The multi-dose study is expected to begin in the first
quarter of 2005. Data from the ongoing Phase 2 single-dose stu... |
| | | 11/02/04 | Amylin Pharmaceuticals Reports Third Quarter Financial Results| Two Diabetes Drug Candidates Under FDA Review
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the third quarter ended
September 30, 2004. The Company reported a net loss of $34.1 million, or
$0.36 per share, for the three months ended September 30, 2004, compared to a
net loss of $37.5 million, or $0.40 per share for the same period in 2003.
For the nine months ended September 30, 2004, the Company reporte... |
| | | 10/26/04 | Amylin Pharmaceuticals to Webcast Third Quarter Results| SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the third
quarter on Tuesday, November 2, 2004 at 12:00 p.m. Eastern/9:00 a.m. Pacific.
The call will be led by Ginger L. Graham, Amylin's President and Chief
Executive Officer. On the same date, Amylin will release financial results
for the third quarter of 2004 prior to the market open.
The call will be webcast live through Amylin's corpora... |
| | | 09/22/04 | Amylin Pharmaceuticals to Present at UBS Global Life Sciences Conference| SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the UBS Global Life Sciences Conference
on Monday, September 27th at 10:00 a.m. ET in New York. Daniel M. Bradbury,
Chief Operating Officer of Amylin Pharmaceuticals, will be providing a
corporate overview, which will include a review of the company's development
programs.
The live presentation and breakout session will both be webcast, and
recordings will be made availab... |
| | | 09/20/04 | Amylin Pharmaceuticals Submits Complete Response to FDA for SYMLIN(R)| SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/-- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced the submission of a complete response to the
U.S. Food and Drug Administration's second approvable letter for SYMLIN(R)
(pramlintide acetate). Resubmission of a complete response after receipt of
an approvable letter is intended to answer all of the questions that need to
be addressed prior to approval. The FDA is expected to respond to this new
submission within six months.
"B... |
| | | 09/17/04 | Amylin Pharmaceuticals to Webcast Update on SYMLIN(R) Regulatory Status| SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast an update on the regulatory status of SYMLIN(R)
(pramlintide acetate) on Monday, September 20, 2004 at 12:00 p.m. ET
(9:00 a.m. PT). SYMLIN(R) is currently under review with the FDA for the
treatment of people with type 1 and insulin-using type 2 diabetes. Ginger L.
Graham, President and Chief Executive Officer of Amylin Pharmaceuticals, will
lead the call.
The call will be webca... |
| | | 09/15/04 | Amylin Pharmaceuticals to Present at Punk Ziegel Diabetes Symposium| SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Punk Ziegel & Company Diabetes
Symposium on Wednesday, September 22, 2004 at 11:55 a.m. ET in New York.
Dennis Kim, MD, Senior Director, Medical Affairs, of Amylin Pharmaceuticals,
will be providing an overview of the exenatide development program.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recordi... |
| | | 09/08/04 | Amylin Pharmaceuticals to Present at Bear Stearns Healthcare Conference| SAN DIEGO, Sept. 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Bear Stearns Healthcare Conference on
Tuesday, September 14, 2004 at 8:00 a.m. ET in New York. Ginger L. Graham,
President and Chief Executive Officer of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation and breakout session will both be webcast, and
recordings will be made available following the events. The webcasts and
recordings... |
| | | 09/03/04 | Amylin Pharmaceuticals to Present at Goldman Sachs Therapeutic Conference| SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Goldman Sachs Therapeutic Conference
on Wednesday, September 8, 2004 at 2:00 p.m. GMT (6:00 a.m. ET) in London,
England. Daniel M. Bradbury, Chief Operating Officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be access... |
| | | 09/02/04 | Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare Conference and BioCentury NewsMakers Conference| SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Thomas Weisel Partners Healthcare
Tailwinds 2004 Conference on Wednesday, September 8, 2004 at 9:10 AM Eastern
Time in Boston and at BioCentury's NewsMakers in the Biotech Industry
Conference on Thursday, September 9, 2004 at 10:30 a.m. Eastern Time in New
York. Mark G. Foletta, Vice President, Finance and Chief Financial Officer of
Amylin Pharmaceuticals, will be providing a... |
| | | 09/01/04 | Exenatide New Drug Application Accepted for Review by the FDA| SAN DIEGO, and INDIANAPOLIS, Sept. 1 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced that the New Drug Application (NDA) for exenatide has been
accepted for review by the Food and Drug Administration (FDA). Exenatide is
the first potential therapy in a new class of drugs under investigation for
the treatment of type 2 diabetes known as incretin mimetics. The NDA for
exenatide was submitted to the FDA on June 29,... |
| | | 08/05/04 | Amylin Pharmaceuticals Reports Second Quarter Financial Results| Exenatide New Drug Application Submitted to FDA as Planned
SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported a net loss of $39.4 million, or $0.42 per share,
for the three months ended June 30, 2004, compared to a net loss of $37.2
million, or $0.40 per share, for the same period in 2003. For the six months
ended June 30, 2004, the company reported a net loss of $76.7 million, or
$0.82 per share, compared to a net loss of $68.0 mi... |
| | | 07/30/04 | Amylin Pharmaceuticals to Webcast Second Quarter Results| SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
second quarter on Thursday, August 5, 2004 at 12:00 p.m. Eastern/9:00 a.m.
Pacific. The call will be led by Ginger L. Graham, Amylin's President and
Chief Executive Officer. On the same date, Amylin will release financial
results for the second quarter of 2004 prior to the market open.
The call will be webcast live through Amylin's corpo... |
| | | 07/26/04 | Successful Completion of Study Comparing Exenatide to Insulin Glargine Results in Milestone Payment from Lilly to Amylin| Patients on Exenatide Experienced Similar Glucose Control Compared
to Patients on Insulin Glargine, With Associated Weight Loss
SAN DIEGO, and INDIANAPOLIS, July 26 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
announced today results from a six-month study that compared exenatide and
insulin glargine in people with type 2 diabetes failing to achieve acceptable
glycemic control with common oral therapies. Patien... |
| | | 06/30/04 | New Drug Application for Exenatide Submitted to FDA for Type 2 Diabetes| SAN DIEGO, and INDIANAPOLIS, June 30 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced the submission of a New Drug Application (NDA) to the U.S.
Food and Drug Administration (FDA) for regulatory approval of exenatide.
Exenatide is the first in a new class of medicines known as incretin mimetics
under investigation for the treatment of type 2 diabetes. In clinical trials,
exenatide has demonstrated reductions in bl... |
| | | 06/06/04 | Scientific Presentations of Exenatide Data Show Improvements in Glucose Control and Restored Insulin Response in People with Type 2 Diabetes| ORLANDO, Fla., June 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) plan to present
detailed results from two clinical studies of exenatide during an oral
abstract presentation at the American Diabetes Association's (ADA) 64th
Scientific Sessions in Orlando, Florida on Tuesday, June 8, 2004. Exenatide
is the first potential therapy in a new class of drugs under investigation for
the treatment of type 2 diabetes known as incret... |
| | | 06/05/04 | Late-Breaking Presentation of Exenatide Pivotal Studies Show Significant Improvements in Glucose Control With Associated Weight Loss in People With Type 2 Diabetes| Data From Pivotal Studies to Form the Basis of a Mid-2004 FDA Submission ORLANDO, Fla., Jun 5, 2004 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals,
Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today presented
detailed 30-week data from two of the three pivotal Phase 3 studies of
exenatide during a late-breaking session at the American Diabetes
Association's (ADA) 64th Scientific Sessions in Orlando, Florida. Exenatide
is the first potential therapy in a new cla... |
| | | 06/03/04 | Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference| SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Goldman Sachs Global Healthcare
Conference on Tuesday, June 8, 2004 at 4:40 p.m. Pacific Time at The
Ritz-Carlton in Dana Point, California. Mark G. Foletta, Vice President,
Finance and Chief Financial Officer of Amylin Pharmaceuticals, will be
providing a corporate overview.
The live presentation and breakout session will both be webcast, and
recordings will be made av... |
| | | 06/02/04 | Amylin Pharmaceuticals to Webcast Data Presented at American Diabetes Association Annual Meeting| SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast data presented at the 64th Scientific Sessions of
the American Diabetes Association in Orlando, Florida on Sunday, June 6, 2004
at 8:00 p.m. Eastern Time. Ginger L. Graham, President and Chief Executive
Officer of Amylin Pharmaceuticals, and other members of the management team
will be presenting.
The presentation will be webcast live, and a recording will be made
available followin... |
| | | 05/21/04 | Amylin Pharmaceuticals Announces Acceptance of 17 Abstracts for Publication at the American Diabetes Association Annual Meeting| Data Disclosure Through Symposia and Company-Sponsored Webcast
SAN DIEGO, May 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that data featuring its two late-stage diabetes
drug candidates, exenatide (synthetic exendin-4) and SYMLIN(R) (pramlintide
acetate) will be presented at the 64th Annual Scientific Sessions of the
American Diabetes Association (ADA) being held in Orlando, Florida from
June 4 - 8, 2004. The meeting is one of the larges... |
| | | 05/14/04 | Amylin Files Resale Registration Statement for Convertible Senior Notes| SAN DIEGO, May 14, 2004 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that it has filed a Form S-3 resale
registration statement with the Securities and Exchange Commission. The
registration statement was in connection with its recent private placement of
$200 million aggregate principal amount of 2.5% convertible senior notes due
2011. Upon being declared effective by the Securities and Exchange
Commission, the registration statement wi... |
| | | 05/13/04 | Amylin Pharmaceuticals to Present at Banc of America Securities Healthcare Conference| SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Banc of America Securities Healthcare
Conference on Thursday, May 20, 2004 at 5:20 p.m. Pacific Time at the Four
Seasons Hotel in Las Vegas, Nevada. Daniel M. Bradbury, Chief Operating
Officer of Amylin Pharmaceuticals, will be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast a... |
| | | 05/03/04 | Amylin Pharmaceuticals to Webcast Annual Meeting of Stockholders Presentation| SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast their Annual Meeting of Stockholders presentation
on Wednesday, May 5, 2004 at 10:00 a.m. Pacific Time from the company's
corporate headquarters in San Diego, CA. Ginger Graham, President and Chief
Executive Officer of Amylin Pharmaceuticals and other members of the
management team will be providing a corporate overview.
The live presentation will be webcast, and a recording will be m... |
| | | 04/30/04 | Amylin Pharmaceuticals To Present At Morgan Stanley Healthcare Conference| SAN DIEGO, Apr 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at Morgan Stanley's Healthcare Unplugged
Conference on Thursday, May 6, 2004 at 10:30 a.m. Eastern Time at the Mandarin
Oriental Hotel in Miami, Florida. Daniel M. Bradbury, Chief Operating Officer
of Amylin Pharmaceuticals, will be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. ... |
| | | 04/28/04 | Amylin Pharmaceuticals Reports First Quarter Financial Results| SAN DIEGO, Apr 28, 2004 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported a net loss of $37.3 million, or $0.40 per share,
for the first quarter ended March 31, 2004, compared to a net loss of
$30.8 million, or $0.34 per share, for the same period in 2003. The Company's
operating activities used approximately $49.4 million of cash in the first
quarter of 2004, compared to $46.5 million in the same period in 2003.
At March 31, 2004, the Com... |
| | | 04/21/04 | Amylin Pharmaceuticals to Webcast First Quarter Results| SAN DIEGO, Apr 21, 2004 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first
quarter of 2004 on Wednesday, April 28, 2004 at 12:00 p.m. Eastern/9:00 a.m.
Pacific. The call will be led by Ginger L. Graham, Amylin's President and
Chief Executive Officer. On the same date, Amylin will release financial
results for the first quarter of 2004 prior to the market open.
The call will be webcast live t... |
| | | 04/08/04 | Amylin Pharmaceuticals to Co-promote Reliant Pharmaceuticals' Family of Cardiovascular Products| SAN DIEGO, April 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) and Reliant Pharmaceuticals, Inc. announced today that the
companies have signed an agreement for Amylin to co-promote Reliant's
cardiovascular products that address cholesterol management and hypertension
to a target group of endocrinologists in the United States. Hypertension and
high cholesterol, common co-morbidities of diabetes, significantly increase
patients' risk for advanced cardiovascular di... |
| | | 04/05/04 | Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $25 Million of Convertible Senior Notes| SAN DIEGO, April 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that the initial purchasers in its recent
private placement of $175 million of 2.5% convertible senior notes due 2011
have elected to exercise their option to purchase an additional $25 million in
principal amount of the notes. The offering is being made pursuant to an
exemption from registration under the Securities Act of 1933, as amended. The
exercise of the option will bring the g... |
| | | 03/31/04 | Amylin Pharmaceuticals, Inc. Announces Pricing Of Convertible Senior Notes| SAN DIEGO, Calif., March 31 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today the pricing of a private
placement of $175 million aggregate principal amount of 2.5% convertible
senior notes due 2011. The offering is being made pursuant to an exemption
from registration under the Securities Act of 1933, as amended. The private
placement is expected to close on April 6, 2004, subject to customary closing
conditions.
The notes will be initially conv... |
| | | 03/30/04 | Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes| SAN DIEGO, March 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) announced today that it intends to offer $150 million of
convertible senior notes for sale in a private placement. The offering will
be made pursuant to an exemption from registration under the Securities Act of
1933, as amended (the "Securities Act"). The convertible senior notes will be
convertible into shares of Amylin common stock. It is expected that the
convertible senior notes will be due in... |
| | | 03/30/04 | Amylin Pharmaceuticals Advances Clinical Pipeline in Diabetes and Obesity| SAN DIEGO, Mar 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) announced today the initiation of a Phase 2 clinical study of
exenatide LAR for type 2 diabetes, the initiation of a Phase 1 clinical study
of AC162352 (PYY 3-36) for obesity, and the completion of enrollment of a
Phase 2 clinical study of AC137 for obesity.
Exenatide LAR is the long-acting release formulation of exenatide, a
compound being developed for the treatment of type 2 diabet... |
| | | 02/27/04 | Amylin Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference| SAN DIEGO, Feb. 27 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Lehman Brothers Global Healthcare
Conference on Thursday, March 04, 2004 at 4:15 p.m. Eastern Time at the Loews
Miami Beach Hotel in Miami Beach, FL. Ginger L. Graham, President and Chief
Executive Officer of Amylin Pharmaceuticals, will be providing a corporate
overview.
The live presentation and breakout session will be webcast separately, and
recordings will be made... |
| | | 02/24/04 | Amylin Pharmaceuticals Reports 2003 Financial Results| SAN DIEGO, Feb 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported a net loss of $122.8 million, or $1.33 per
share, for the fiscal year ended December 31, 2003, compared to a net loss of
$109.8 million, or $1.39 per share, for the year ended December 31, 2002. For
the fourth quarter ended December 31, 2003, the Company reported a net loss of
$17.3 million, or $0.19 per share, compared to a net loss of $29.2 million, or
$0.36 per share,... |
| | | 02/19/04 | Amylin Pharmaceuticals to Webcast Year-End Results| SAN DIEGO, Feb 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
fourth quarter of 2003 on Tuesday, February 24, 2004 at 12:00 p.m.
Eastern/9:00 a.m. Pacific. The call will be led by Ginger L. Graham, Amylin's
President and Chief Executive Officer. The Company will release financial
results for the fourth quarter and fiscal year ended December 31, 2003 that
morning before the market opens.
... |
| | | 02/12/04 | Amylin Pharmaceuticals to Present At Roth Capital Partners Growth Stock Conference| SAN DIEGO, Feb. 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Roth Capital Partners Growth Stock
Conference on Tuesday, February 17, 2004 at 9:00 a.m. Pacific Time at
The St. Regis Monarch Beach Resort in Dana Point, CA. Mark G. Foletta, Vice
President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, will
be providing a corporate overview.
The presentation will be webcast live by Roth Capital Partners, and a
record... |
| | | 01/22/04 | Amylin Pharmaceuticals to Present at U.S. Bancorp Piper Jaffray Healthcare Conference| SAN DIEGO, Jan. 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the U.S. Bancorp Piper Jaffray Healthcare
Conference on Tuesday, January 27, 2004 at 10:00 a.m. Eastern Time at The
Pierre Hotel in New York, New York. Mark G. Foletta, Vice President, Finance
and Chief Financial Officer of Amylin Pharmaceuticals, will be providing a
corporate overview and an update on recent company activities. Following the
presentation, there will be a breako... |
| | | 01/12/04 | Amylin Pharmaceuticals CEO to Provide Corporate Update at JPMorgan Healthcare Conference| SAN FRANCISCO, Jan. 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be giving a corporate presentation this morning at
10:00 a.m. PST at the JPMorgan Healthcare conference in San Francisco,
California. The presentation, to be given by Ginger L. Graham, President and
CEO, will include updates on Amylin's current development programs and will
outline the company's corporate goals for 2004. Following the presentation,
there will be a breakout session for confer... |
| | | 01/09/04 | Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference| SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) will be presenting at the JPMorgan Healthcare Conference on Monday, January 12, 2004 at 10:00 a.m. Pacific Time in San Francisco, California. Ginger L. Graham, President and Chief Executive Officer of Amylin Pharmaceuticals, will be providing a corporate overview and an update on recent company activities. The company will also participate in a breakout session immediately following the presentation at... |
| | | 01/07/04 | Amylin Pharmaceuticals Withdraws Swiss Regulatory Application for SYMLIN(R)| SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced receipt of correspondence from the Swiss Agency
for Therapeutic Products (Swissmedic) indicating that SYMLIN(R) could not be
approved for marketing in Switzerland based on data received to date. The
Swissmedic indicated that they require additional clinical information to
demonstrate the benefits of SYMLIN(R) therapy relative to risks associated
with adverse events, including nausea and... |
| | | 01/06/04 | Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference| SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the JPMorgan Healthcare Conference on
Monday, January 12, 2004 at 10:00 a.m. Pacific Time in San Francisco,
California. Ginger L. Graham, President and Chief Executive Officer of Amylin
Pharmaceuticals, will be providing a corporate overview and an update on
recent company activities. The company will also participate in a breakout
session immediately following the presentation a... |
| | | 12/19/03 | Amylin Pharmaceuticals Announces Informal Inquiry by the Securities and Exchange Commission| SAN DIEGO, Dec. 19 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that the Securities and Exchange Commission is
conducting an informal inquiry related to recent communications about Amylin's
drug candidate, SYMLIN(R). The Company believes that this inquiry relates to
compliance with Regulation FD and intends to fully cooperate.
This press release contains forward-looking statements, including
statements regarding the Company's beliefs, which i... |
| | | 12/18/03 | Amylin and Lilly Announce Achievement of First Exenatide Development Milestones| Successful Completion of Phase 3 Pivotal Studies Results in Lilly $35 Million Payment to Amylin SAN DIEGO, and INDIANAPOLIS, Dec 18, 2003 /PRNewswire-FirstCall via Comtex/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company
(NYSE: LLY) today announced the achievement of the first development
milestones in the global collaboration agreement for exenatide (synthetic
exendin-4). The milestones mark the successful completion of the exenatide
Phase 3 pivotal studies and a... |
| | | 12/18/03 | Amylin Pharmaceuticals to Webcast Corporate Update Conference Call| SAN DIEGO, Dec 18, 2003 /PRNewswire-FirstCall via Comtex/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) plans to webcast a Corporate Update Conference Call on
Thursday, December 18, 2003 at 4:30 p.m. Eastern/1:30 p.m. Pacific. The call
will be led by Ginger L. Graham, Amylin's President and Chief Executive
Officer. The Company will provide updates on the SYMLIN(R) (pramlintide
acetate) and exenatide (synthetic exendin-4) development programs.
The call will be webcast live through Amy... |
| | | 12/17/03 | Amylin Pharmaceuticals Receives Second Approvable Letter for SYMLIN(R)| SAN DIEGO, Dec. 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that the U.S. Food and Drug Administration
(FDA) has issued a second approvable letter for SYMLIN(R) (pramlintide
acetate), Amylin's lead drug candidate being studied for the treatment of
people with type 1 and insulin-using type 2 diabetes. The FDA has requested
additional clinical data to identify a patient population and method of use
for SYMLIN(R) where there is no increased risk o... |
| | | 12/11/03 | Amylin Pharmaceuticals Files Shelf Registration Statement| SAN DIEGO, Dec 11, 2003 /PRNewswire-FirstCall via Comtex/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that it has filed a shelf registration
statement with the Securities and Exchange Commission (SEC). Upon being
declared effective by the SEC, the shelf registration statement will allow the
Company to sell up to $300 million of various securities in one or more
offerings in the future. The terms of any offering will be established at the
time of sale.
The shelf re... |
| | | 11/24/03 | Amylin Pharmaceuticals to Webcast Corporate Update Conference Call| SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) plans to webcast a Corporate Update Conference Call on Tuesday,
November 25, 2003 at 10:00 a.m. Eastern/7:00 a.m. Pacific. The call will be
led by Ginger L. Graham, Amylin's President and Chief Executive Officer.
The call will be webcast live through Amylin's corporate website and a
recording will be made available following the close of the call. To access
the webcast, please log on to www.amy... |
| | | 11/24/03 | Positive Results from Final Exenatide Pivotal Study Mark Successful Completion of Phase 3| Statistically Significant Improvements in Glucose
Control and Weight Seen Across All Long-term Studies
SAN DIEGO and INDIANAPOLIS, Nov. 24 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced positive results from the final Phase 3 pivotal study of
exenatide (synthetic exendin-4), marking the conclusion of the long-term human
clinical trials required for a regulatory submission to the U.S. Food and ... |
| | | 11/10/03 | Exenatide Continues to Generate Positive Results in Second of Three Phase 3 Studies| SAN DIEGO, and INDIANAPOLIS, Nov. 10 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced that exenatide (synthetic exendin-4) produced statistically
significant, dose-dependent reductions in the glucose control endpoint in a
seven-month Phase 3 pivotal study in people with type 2 diabetes failing to
achieve target blood glucose levels with sulfonylurea alone. Reductions in
average blood glucose were similar to reduct... |
| | | 11/04/03 | Amylin Pharmaceuticals Reports Third Quarter Financial Results| SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported financial results for the third quarter ended
September 30, 2003. The Company reported a net loss of $37.5 million, or
$0.40 per share, and $105.5 million, or $1.15 per share, for the three and
nine months ended September 30, 2003. These results compare with reported
losses of $31.3 million, or $0.39 per share, and $80.6 million, or $1.03 per
share, for the comparable periods in 2002. ... |
| | | 10/31/03 | Amylin Pharmaceuticals Names Michael Hanley As Vice President of Discovery Research| SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Michael Hanley, Ph.D. has joined the
Company as Vice President, Discovery Research. Dr. Hanley has served on the
Scientific Advisory Board of Amylin since 1992 and for the last six months has
served as a senior scientific advisor to the Company. Dr. Hanley will oversee
Amylin's discovery research in the areas of research chemistry, in-vivo
modeling and cell and molecular biology.... |
| | | 10/30/03 | Amylin Pharmaceuticals to Webcast Third Quarter Company Update Conference Call| SAN DIEGO, Oct 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) plans to webcast its Quarterly Update Conference Call for the
third quarter of 2003 on Tuesday, November 4, 2003 at 12:00 p.m. Eastern/9:00
a.m. Pacific. The call will be led by Ginger L. Graham, Amylin's President
and Chief Executive Officer. The Company will release financial results for
the third quarter that morning before the market opens.
The call will be webcast live throug... |
| | | 09/29/03 | Amylin Resale Registration Statement Declared Effective by SEC| SAN DIEGO, Sep 29, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that the Securities and Exchange Commission has
declared effective the Form S-3 resale registration statement that the company
filed with the Securities and Exchange Commission on August 15, 2003. Amylin
filed and requested the effectiveness of the resale registration statement to
satisfy certain of its obligations under a registration rights agreement that
Amylin enter... |
| | | 09/18/03 | Amylin Pharmaceuticals to Present at 2003 Morgan Stanley Convertible Conference and UBS Global Life Sciences Conference| San Diego, Sept. 18 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the 2003 Morgan Stanley Convertible
Conference on Tuesday, September 23, 2003 at 11:10 AM Mountain Time in
Telluride, CO and at the UBS Global Life Sciences Conference on Thursday,
September 25, 2003 at 2:30 PM Eastern Time in New York, NY. Mark G. Foletta,
Amylin's Vice President of Finance and Chief Financial Officer, will be
presenting at the Morgan Stanley conference. Danie... |
| | | 09/15/03 | Amylin Pharmaceuticals Elects Joseph P. Sullivan to Board of Directors| San Diego, Sept. 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Joseph P. Sullivan has been elected to the
company's board of directors and audit committee effective immediately.
Mr. Sullivan is currently Chairman of the Board of Advisors of RAND Health
and Vice Chairman of the Board of the UCLA Medical Center. He has previously
served as Chairman, Chief Executive Officer and a Director of Protocare, Inc.,
and as Chairman, Chief Executi... |
| | | 09/03/03 | Amylin Pharmaceuticals to Present at Bear Stearns Healthcare Conference And Roth Capital Partners New York Conference| SAN DIEGO, Sep 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be in New York to present at the Bear Stearns Healthcare
Conference on Monday, September 8, 2003 at 10:30 AM Eastern Time and at the
Roth Capital Partners New York Conference on Tuesday, September 9, 2003 at
8:30 AM Eastern Time. Mark G. Foletta, Vice President of Finance and Chief
Financial Officer of Amylin Pharmaceuticals, will be providing a corporate
overview and an update on ... |
| | | 08/29/03 | Amylin Pharmaceuticals to Present at BioCentury Newsmakers Conference And Thomas Weisel Healthcare Conference| SAN DIEGO, Aug. 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at BioCentury's Newsmakers in the Biotech
Industry Conference on Thursday, September 4, 2003 at 9:00 AM Eastern Time in
New York, and at the Thomas Weisel Partners' Healthcare Tailwinds 2003
Conference on Friday, September 5, 2003 at 10:00 AM Eastern Time in Boston.
Ginger L. Graham, President and Chief Executive Officer of Amylin
Pharmaceuticals, will be providing a corporate overvi... |
| | | 08/25/03 | Exenatide Open-Label Study Continues to Show Promise for People With Type 2 Diabetes|
New Data at International Diabetes Meeting Demonstrate Nearly
Half of Patients Reach Target A1C Levels, Despite Previous
Failure With Oral Therapies
PARIS, Aug. 25 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.,
(Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced today that
results from a Phase 3 open-label study of exenatide, the first in a new class
of therapies for the treatment of type 2 diabetes known as Increti... |
| | | 08/21/03 | Amylin Pharmaceuticals Announces Plans for 18th Congress of the International Diabetes Federation| SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that it will be presenting eight abstracts at
the 18th International Diabetes Federation Congress (IDF) being held in Paris,
France from August 24 - 29, 2003. The meeting is the largest European meeting
for endocrinologists and other health care professionals involved in diabetes
research and the delivery of diabetes care.
Amylin's research continues to play a role in expanding t... |
| | | 08/15/03 | Amylin Files Resale Registration Statement for Convertible Senior Notes| SAN DIEGO, Aug. 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that it has filed a Form S-3 resale
registration statement with the Securities and Exchange Commission. Amylin
has filed the resale registration statement to satisfy certain of its
obligations under a registration rights agreement that Amylin entered into in
connection with its recent private placement of $175 million in aggregate
principal amount of 2.25% convertible senior notes due ... |
| | | 08/14/03 | Amylin Pharmaceuticals Reports Second Quarter Financial Results| Company Submits Amendment to New Drug Application for SYMLIN(R) to the FDA And Successfully Completes $150 Million Convertible Debt Offering in Second Quarter SAN DIEGO, Aug 14, 2003 /PRNewswire-FirstCall via Comtex/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today reported its financial results for the second quarter
ended June 30, 2003. The Company reported a net loss of $37.2 million, or
$0.40 per share, and $68.0 million, or $0.74 per share for the three and six
months ended June ... |
| | | 08/11/03 | Amylin Pharmaceuticals to Webcast Second Quarter Company Update Conference Call| SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) plans to webcast its Quarterly Update Conference Call for the
second quarter of 2003 on Thursday, August 14, 2003 at 12:00 p.m.
Eastern/9:00 a.m. Pacific. The call will be led by Joseph C. Cook, Jr.,
Amylin's Chairman and Chief Executive Officer. The Company will release
financial results for the second quarter that morning before the market opens.
The call will be webcast live through Amylin's... |
| | | 08/06/03 | First of Three Phase 3 Exenatide Studies Achieves Positive Results in Type 2 Diabetes| Nearly Half of Patients on Target Exenatide Dose Achieve ADA Treatment Goal
SAN DIEGO and INDIANAPOLIS, Aug. 6 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced that exenatide (synthetic exendin-4) produced statistically
significant, dose-dependent reductions in the primary glucose control endpoint
in a seven-month Phase 3 pivotal study in people with type 2 diabetes failing
to achieve target blood glucose level... |
| | | 07/29/03 | Amylin Pharmaceuticals Reports Encouraging Phase 2 Results From GLP-1 Program In Severe Congestive Heart Failure| SAN DIEGO, Jul 29, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced encouraging results from a Phase 2 dose-
titration study of drug candidate AC2592, which utilizes continuous
subcutaneous infusion of glucagon-like peptide 1 (GLP-1) for the treatment of
congestive heart failure (CHF) in patients ineligible for transplant. GLP-1
is a naturally occurring hormone produced in the gut.
This open-label exploratory study included 14 subje... |
| | | 07/21/03 | Amylin Pharmaceuticals Repays Johnson & Johnson Loans From Prior SYMLIN(R) Collaboration| SAN DIEGO, Jul 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced the early repayment of its outstanding loans to
Johnson & Johnson. Amylin paid Johnson & Johnson $62.5 million, representing
a 7% discount to the total loan obligation as of the repayment date. These
loans were advanced prior to 1998, pursuant to an earlier collaboration on
Amylin's lead diabetes drug candidate SYMLIN(R) (pramlintide acetate), and
collectively accrued ... |
| | | 07/18/03 | Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $25 Million of Convertible Senior Notes| SAN DIEGO, Jul 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that the initial purchasers in its recent
private placement of $150 million of 2.25% convertible senior notes due in
2008 have elected to exercise their option to purchase an additional $25
million in principal amount of the notes. The exercise of the option will
bring the gross proceeds of the private placement to $175 million upon closing
of the option exercise. The ... |
| | | 07/14/03 | Amylin Pharmaceuticals Joins the Russell 1000(R) Index| SAN DIEGO, July 14 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that it has been added to the Russell 1000(R)
Index issued by Frank Russell Company. The reconstituted index membership,
announced last week, went into effect July 1, 2003 and remains in place for
one year. The Russell 1000(R) Index measures the performance of the
1,000 largest U.S. companies based on total market capitalization.
Membership in Russell's 21 U.S. equity indexes is ... |
| | | 07/14/03 | Amylin Pharmaceuticals Appoints Joni Harvey As Vice President of Quality Assurance| SAN DIEGO, July 14 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that Joni Harvey has joined the Company as Vice
President of Quality Assurance.
Ms. Harvey joins Amylin Pharmaceuticals from Alliance Pharmaceutical
Corp., where she served as Vice President, Operations. Prior to joining
Alliance, she served as Vice President of Operations at Molecular Biosystems,
Inc. where she was involved with numerous Quality initiatives. In addition,
she held... |
| | | 07/08/03 | Data From Two Exenatide Studies Demonstrate Potential For the Treatment of Type 2 Diabetes| Recent Published Results Illustrate the Compound's Multiple
Mechanisms of Action
SAN DIEGO, and INDIANAPOLIS, July 8 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
announced today that clinical trial results published on exenatide, a first-
in-class compound in development for the treatment of type 2 diabetes,
demonstrate significantly reduced fasting and postprandial (post-meal) glucose
concentr... |
| | | 06/18/03 | Amylin Pharmaceuticals, Inc. Announces Pricing of Convertible Senior Notes| SAN DIEGO, June 18 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today the pricing of a
private placement of $150 million aggregate principal amount of
2.25% convertible senior notes due 2008. The offering is being made pursuant
to an exemption from registration under the Securities Act of 1933, as
amended. The private placement is expected to close on June 23, 2003, subject
to customary closing conditions.
The notes will be initially convertible ... |
| | | 06/16/03 | Amylin Pharmaceuticals Submits New Drug Application Amendment for SYMLIN(R) For the Treatment of Diabetes| SAN DIEGO, June 16 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced the submission of
a New Drug Application (NDA) amendment for its lead diabetes drug candidate,
SYMLIN(R) (pramlintide acetate), to the U.S. Food and Drug Administration
(FDA). The Company is seeking approval to market SYMLIN(R) as an adjunctive
therapy to insulin for the treatment of people with type 1 or type 2 diabetes
who use insulin. The amendment includes results from a dose-titr... |
| | | 06/16/03 | Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes| SAN DIEGO, June 16 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that it intends to
offer $150,000,000 of convertible senior notes for sale in a private
placement. The offering will be made pursuant to an exemption from
registration under the Securities Act of 1933, as amended (the "Securities
Act"). It is expected that the convertible senior notes will be due in 2008.
Amylin intends to use the net proceeds of this offering for research and
... |
| | | 06/15/03 | Exenatide Open-Label Study Shows Encouraging Results in People With Type 2 Diabetes| Over 50% of Patients Reach Target A1C Levels, Despite Previous Failure With Oral Therapies SAN DIEGO, and INDIANAPOLIS, Jun 15, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly
and Company (NYSE: LLY) announced today that results from a Phase 3 open-label
study of exenatide, a novel drug candidate for the treatment of type 2
diabetes, showed that more than half of the participants who completed
20 weeks of treatment achieved average gluco... |
| | | 06/12/03 | Amylin Pharmaceuticals to Webcast Investor Update From American Diabetes Association Annual Meeting| SAN DIEGO, June 12 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be providing an update for
investors in conjunction with the 63rd Scientific Sessions of the American
Diabetes Association. The presentation will take place on Sunday, June 15,
2003 at 7:30 p.m. Central Time. Amylin Senior Management will be providing an
overview of some of the data being presented this weekend on its two late-
stage diabetes drug candidates, SYMLIN(R) (pramlintide acetate) and ... |
| | | 06/09/03 | Amylin Pharmaceuticals Names New Chief Executive Officer| Expands Executive Team for Growth of Company
SAN DIEGO, June 9 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that Ginger L.
Graham has been named President and Chief Executive Officer, effective
September 1, 2003. Graham recently worked with Guidant Corporation, a medical
technology company, where she was Group Chairman, Office of the President.
She was responsible for Guidant's global operations, producing revenues in
excess of $3 billion. Pr... |
| | | 06/06/03 | Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference| SAN DIEGO, June 6 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Goldman
Sachs Global Healthcare Conference on Wednesday, June 11, 2003 at 4:40 p.m.
Pacific Time at The Ritz-Carlton in Dana Point, California. Joseph C.
Cook, Jr., Chairman of the Board and Chief Executive Officer of Amylin
Pharmaceuticals, will be providing a corporate overview and an update on
recent company activities.
This presentation will be webcast live by Goldm... |
| | | 06/02/03 | Exenatide Open-Label Data Accepted for Late-Breaking Presentation at American Diabetes Association Annual Meeting| SAN DIEGO and INDIANAPOLIS, June 2 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company
(NYSE: LLY) announced today that an abstract containing preliminary results
from an ongoing Phase 3, open-label study of exenatide, a first-in-class drug
candidate for the treatment of type 2 diabetes, was posted today on the Web
site of the American Diabetes Association (ADA). Data from the posted
abstract, along with other data not yet available, will be pres... |
| | | 06/02/03 | Amylin Pharmaceuticals Announces Plans For American Diabetes Association Annual Meeting| SAN DIEGO, Jun 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it will be
presenting over a dozen abstracts at the 63rd Annual Scientific Sessions of
the American Diabetes Association (ADA) being held in New Orleans from
June 13 - 17, 2003. The meeting is one of the largest for endocrinologists
and other health care professionals involved in diabetes research and the
delivery of diabetes care. Two late-breaking presentations wi... |
| | | 05/22/03 | Amylin Pharmaceuticals Expands Marketing and Sales Management Team| SAN DIEGO, May 22, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), as part of its commercial
strategy, has announced the addition to its management team of Dwayne M.
Elwood as Senior Vice President, Marketing and Craig Eberhard as Vice
President, Sales. Elwood and Eberhard will be focused on preparing for the
potential commercialization of Amylin's two late-stage diabetes product
candidates, SYMLIN(R) (pramlintide acetate) and exenatide (synthetic
ex... |
| | | 05/19/03 | Amylin Pharmaceuticals Reports Data From SYMLIN(R) Dose-Titration Study| SAN DIEGO, May 19 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that results from
a dose-titration study of its diabetes drug candidate SYMLIN(R) (pramlintide
acetate) met prospectively defined parameters for the non-inferiority
objective of the study. The dose-titration study included 296 subjects with
type 1 diabetes who were intensively managing their disease with either
multiple daily insulin injections or insulin pump therapy. In addition to
... |
| | | 05/07/03 | Amylin Pharmaceuticals Reports First Quarter Financial Results| Company Successfully Completes $165 Million Public Offering in First Quarter SAN DIEGO, May 7, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported a net loss of
$30.8 million, or $0.34 per share, for the first quarter ended March 31, 2003,
compared to a net loss of $22.1 million, or $0.30 per share, for the same
period in 2002.
The Company completed a follow-on stock offering during the first quarter
of 2003, selling 10.5 million shares... |
| | | 05/02/03 | Amylin Pharmaceuticals to Webcast First Quarter Company Update Conference Call| SAN DIEGO, May 2 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) plans to webcast its Quarterly
Update Conference Call for the first quarter of 2003 on Wednesday, May 7, 2003
at 12:00 p.m. Eastern/9:00 a.m. Pacific. The call will be led by Joseph C.
Cook, Jr., Amylin's Chairman and Chief Executive Officer. The Company will
release financial results for the first quarter that morning before the market
opens.
The call will be webcast live through Amylin's corpo... |
| | | 04/28/03 | Amylin Pharmaceuticals to Present At Morgan Stanley's Healthcare Unplugged Conference| SAN DIEGO, April 28 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at Morgan
Stanley's Healthcare Unplugged Conference on Thursday, May 1, 2003 at 8:15
a.m. Eastern Time at the Mandarin Oriental Hotel in Miami, Florida. Joseph C.
Cook, Jr., Chairman of the Board and Chief Executive Officer of Amylin
Pharmaceuticals, will be providing a corporate overview and an update on
recent company activities.
This presentation will be webcast live by M... |
| | | 03/31/03 | Amylin Pharmaceuticals Submits Additional SYMLIN(R) Information to theSwiss Regulatory Authorities| - SYMLIN(R) Dose-titration Study Completes in the Clinic - SAN DIEGO, Mar 31, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that it has
submitted a response to inquiries from the Swiss Regulatory Authorities
(Swissmedic) in connection with its review of the marketing application for
diabetes drug candidate SYMLIN(R) (pramlintide acetate). The response
includes an interim summary of 16-week data from the SYMLIN(R) dose-titration
study... |
| | | 03/24/03 | Amylin Pharmaceuticals to Present At Banc of America Securities Healthcare Conference| SAN DIEGO, Mar 24, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Banc of America
Securities Healthcare Conference on Wednesday, March 26, 2003 at 10:20 a.m.
Pacific Time at the Four Seasons Hotel in Las Vegas, Nevada. Daniel M. Bradbury,
Executive Vice President of Amylin Pharmaceuticals, will be providing a
corporate overview and an update on recent company activities.
This presentation will be webcast live by Banc of Am... |
| | | 03/19/03 | Amylin, Lilly and Alkermes Announce Preliminary Phase 2 Results and Submission Of IND for Exenatide LAR (Sustained Release) Program in Type 2 Diabetes| SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., Mar 19, 2003 /PRNewswire via
COMTEX/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company
(NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced preliminary
pharmacokinetic results from the first Phase 2 study of exenatide LAR, formerly
referred to as AC2993 LAR. The results from this study verify that sustained
levels of exenatide are possible and support the continuation of the Phase 2
program. Based on these data and... |
| | | 03/13/03 | Amylin Pharmaceuticals to Present at Roth Capital Partners Growth Stock Conference| SAN DIEGO, Mar 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Roth Capital
Partners Growth Stock Conference on Monday, March 17, 2003 at 7:30 a.m. Pacific
Time at the St. Regis Monarch Beach Resort & Spa in Dana Point, California. Mark
G. Foletta, Vice President, Finance and Chief Financial Officer of Amylin
Pharmaceuticals, will be providing a corporate overview and an update on recent
company activities.
This presen... |
| | | 02/27/03 | Amylin Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference| SAN DIEGO, Feb 27, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Lehman Brothers
Global Healthcare Conference on Tuesday, March 4, 2003 at 10:45 a.m. Eastern
Time at the Loews Miami Beach Hotel in Miami Beach, Florida. Joseph C. Cook,
Jr., Chairman and CEO of Amylin Pharmaceuticals, will be providing a corporate
overview and an update on recent company activities.
This presentation will be webcast live by Lehman Brothers,... |
| | | 02/20/03 | Amylin Pharmaceuticals Reports 2002 Financial Results| Significant Progress Made on SYMLIN(R) (pramlintide acetate) and Exenatide In 2002 SAN DIEGO, Feb 20, 2003 /PRNewswire-FirstCall via COMTEX/ --Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported a net loss of $109.8
million, or $1.39 per share, for the fiscal year ended December 31, 2002,
compared to a net loss of $72.0 million, or $1.09 per share, for the year ended
December 31, 2001. For the fourth quarter ended December 31, 2002, the Company
reported a net loss of $29.2 million... |
| | | 02/13/03 | Amylin Pharmaceuticals to Webcast Fourth Quarter Company Update Conference Call| SAN DIEGO, Feb 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) plans to webcast its Quarterly Update
Conference Call for the fourth quarter of 2002 on Thursday, February 20, 2003 at
10:00 a.m. Eastern/7:00 a.m. Pacific. The call will be led by Joseph C. Cook,
Jr., Amylin's Chairman and Chief Executive Officer. The Company will release
financial results for the fourth quarter that morning before the market opens.
The call will be webcast live thr... |
| | | 01/29/03 | Amylin Pharmaceuticals Completes Acquisition of Rights To Phase 2 GLP-1 Program for Congestive Heart Failure|
SAN DIEGO, Jan. 29 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that it has
completed the acquisition from Restoragen, Inc. of rights to a Phase 2 program
utilizing continuous infusion of glucagon-like peptide 1 (GLP-1), targeted for
the treatment of congestive heart failure (CHF) in patients ineligible for
transplant. GLP-1 is a naturally occurring hormone produced in the gut in
response to food intake. In connection with this tra... |
| | | 01/22/03 | Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters|
SAN DIEGO, Jan. 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasda |
|
|
